Repligen (RGEN) 10-Q 18 Nov 24 2024 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2024	Nov. 12, 2024
Cover [Abstract]
Amendment Flag	false
Document Type	10-Q
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000730272
Current Fiscal Year End Date	--12-31
Document Period End Date	Sep. 30, 2024
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Securities Act File Number	000-14656
Entity Registrant Name	REPLIGEN CORP
Entity Filer Category	Large Accelerated Filer
Trading Symbol	RGEN
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2729386
Entity Address, Address Line One	41 Seyon Street, Bldg. 1, Suite 100
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02453
City Area Code	781
Entity Shell Company	false
Smaller reporting company	false
Emerging growth company	false
Local Phone Number	250-0111
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		56,026,725

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 783,964		$ 751,323
Accounts receivable, net of reserves of $1,961 and $2,122 at September 30, 2024 and December 31, 2023, respectively	129,026		124,161
Inventories, net	182,465		202,321
Prepaid expenses and other current assets	36,115		33,541
Total current assets	1,131,570		1,111,346
Property, plant and equipment, net	202,583		207,440
Intangible assets, net	380,754		406,957
Goodwill	987,620		987,120
Deferred tax assets	101		1,530
Operating lease right of use assets	127,268		115,515
Other noncurrent assets	748		1,277
Total noncurrent assets	1,699,074		1,719,839
Total assets	2,830,644		2,831,185
Current liabilities:
Accounts payable	21,357		19,563
Operating lease liability	12,171		5,631
Current contingent consideration	13,936		12,983
Accrued liabilities	60,902		57,313
Convertible Senior Notes due 2024, net	0		69,452
Total current liabilities	108,366		164,942
Convertible Senior Notes due 2028, net	521,607		510,143
Deferred tax liabilities	33,686		39,324
Noncurrent operating lease liability	138,693		126,578
Noncurrent contingent consideration	0		14,070
Other noncurrent liabilities	11,606		11,283
Total noncurrent liabilities	705,592		701,398
Total liabilities	813,958		866,340
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	0		0
Common stock, $0.01 par value; 80,000,000 shares authorized; 56,026,725 shares at September 30, 2024 and 55,766,078 shares at December 31, 2023 issued and outstanding	560		558
Additional paid-in capital	1,609,526		1,569,227
Accumulated other comprehensive loss	(34,623)		(37,808)
Retained earnings	441,223		432,868
Total stockholders' equity	2,016,686	$ 1,984,438	1,964,845	$ 1,973,743	$ 1,956,859	$ 1,910,700
Total liabilities and stockholders' equity	$ 2,830,644		$ 2,831,185

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounts receivable, reserve for doubtful accounts	$ 1,961	$ 2,122	$ 1,365
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000	80,000,000
Common stock, shares issued	56,026,725	55,766,078	55,557,698
Common stock, shares outstanding	56,026,725	55,766,078	55,557,698

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Revenue	$ 154,871	$ 141,192	$ 466,892	$ 465,741
Costs and operating expenses:
Cost of goods sold	77,383	104,634	231,088	265,786
Research and development	9,710	10,577	31,523	32,437
Selling, general and administrative	75,610	55,582	202,894	160,954
Contingent consideration	0	(34,292)	0	(31,266)
Total costs and operating expenses	162,703	136,501	465,505	427,911
Income from operations	(7,832)	4,691	1,387	37,830
Other income (expenses):
Investment income	9,130	6,662	27,534	18,112
Interest expense	(5,122)	(408)	(15,269)	(1,227)
Amortization of debt issuance costs	(429)	(459)	(1,432)	(1,373)
Other income (expenses)	3,104	895	(647)	1,500
Other income (expenses), net	6,683	6,690	10,186	17,012
Income before income taxes	(1,149)	11,381	11,573	54,842
Income tax (benefit) provision	(495)	(5,542)	3,218	2,796
Net income	$ (654)	$ 16,923	$ 8,355	$ 52,046
Earnings per share:
Basic	$ (0.01)	$ 0.3	$ 0.15	$ 0.93
Diluted (Note 13)	$ (0.01)	$ 0.3	$ 0.15	$ 0.91
Weighted average common shares outstanding:
Basic	56,012	55,766	55,896	55,688
Diluted (Note 13)	56,012	56,940	56,315	56,933
Net Income (Loss)	$ (654)	$ 16,923	$ 8,355	$ 52,046
Other comprehensive income (loss):
Foreign currency translation adjustment	9,822	(5,880)	3,185	(8,972)
Comprehensive income	9,168	11,043	11,540	43,074
Product
Revenue:
Revenue	154,834	141,156	466,784	465,630
Royalty and other revenue
Revenue:
Revenue	$ 37	$ 36	$ 108	$ 111

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings	FlexBiosys, Inc.	FlexBiosys, Inc. Common Stock	FlexBiosys, Inc. Additional Paid-In Capital
Translation adjustment	$ (8,972)			$ (8,972)
Balance at Dec. 31, 2022	1,910,700	$ 556	$ 1,547,266	(34,394)	$ 397,272
Beginning Balance (in shares) at Dec. 31, 2022		55,557,698
Net Income (Loss)	52,046				52,046
Conversion of debt	(13)	$ 0	(13)
Conversion of debt (in shares)		8
Exercise of stock options and vesting of stock units	356	$ 3	353
Exercise of stock options and vesting of stock units (in shares)		212,589
Tax withholding on vesting of restricted stock units	(12,178)	$ (1)	(12,177)
Tax withholding on vesting of restricted stock units (in shares)		(69,625)
Issuance of common stock pursuant to the acquisition						$ 5,465	$ 0	$ 5,465
Issuance of common stock pursuant to the acquisition, (in shares)							31,415
Issuance of common stock pursuant to contingent consideration earnout payment	7,229	$ 0	7,229
Issuance of common stock pursuant to contingent consideration earnout payments		42,621
Stock-based compensation expense	19,110		19,110
Balance at Sep. 30, 2023	1,973,743	$ 558	1,567,233	(43,366)	449,318
Ending Balance (in shares) at Sep. 30, 2023		55,774,706
Balance at Jun. 30, 2023	1,956,859	$ 557	1,561,393	(37,486)	432,395
Beginning Balance (in shares) at Jun. 30, 2023		55,744,896
Net Income (Loss)	16,923				16,923
Conversion of debt	(10)		(10)
Conversion of debt (in shares)		2
Exercise of stock options and vesting of stock units	294	$ 1	293
Exercise of stock options and vesting of stock units (in shares)		36,195
Tax withholding on vesting of restricted stock units	(1,038)	$ 0	(1,038)
Tax withholding on vesting of restricted stock units (in shares)		(6,387)
Issuance of common stock pursuant to the acquisition						$ 222		$ 222
Stock-based compensation expense	6,373		6,373
Balance at Sep. 30, 2023	1,973,743	$ 558	1,567,233	(43,366)	449,318
Ending Balance (in shares) at Sep. 30, 2023		55,774,706
Translation adjustment	(5,880)			(5,880)
Balance at Dec. 31, 2023	1,964,845	$ 558	1,569,227	(37,808)	432,868
Beginning Balance (in shares) at Dec. 31, 2023		55,766,078
Net Income (Loss)	8,355				8,355
Conversion of debt	(114)	$ 1	(115)
Conversion of debt (in shares)		100,944
Exercise of stock options and vesting of stock units	2,366	$ 2	2,364
Exercise of stock options and vesting of stock units (in shares)		179,335
Tax withholding on vesting of restricted stock units	(9,404)	$ (1)	(9,403)
Tax withholding on vesting of restricted stock units (in shares)		(51,040)
Issuance of common stock pursuant to contingent consideration earnout payment	5,742	$ 0	5,742
Issuance of common stock pursuant to contingent consideration earnout payments		31,408
Stock-based compensation expense	41,711		41,711
Balance at Sep. 30, 2024	2,016,686	$ 560	1,609,526	(34,623)	441,223
Ending Balance (in shares) at Sep. 30, 2024		56,026,725
Translation adjustment	9,822			9,822
Balance at Jun. 30, 2024	1,984,438	$ 559	1,586,447	(44,445)	441,877
Beginning Balance (in shares) at Jun. 30, 2024		55,902,860
Net Income (Loss)	(654)				(654)
Conversion of debt	(7)	$ 1	(8)
Conversion of debt (in shares)		100,942
Exercise of stock options and vesting of stock units	577	$ 0	577
Exercise of stock options and vesting of stock units (in shares)		26,854
Tax withholding on vesting of restricted stock units	(545)	$ 0	(545)
Tax withholding on vesting of restricted stock units (in shares)		(3,931)
Stock-based compensation expense	23,055		23,055
Balance at Sep. 30, 2024	2,016,686	$ 560	$ 1,609,526	(34,623)	$ 441,223
Ending Balance (in shares) at Sep. 30, 2024		56,026,725
Translation adjustment	$ 3,185			$ 3,185

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net Income (Loss)	$ 8,355	$ 52,046
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	51,306	51,295
Amortization of debt discount and issuance costs	11,628	1,373
Stock-based compensation	41,711	19,110
Deferred income taxes, net	(4,163)	(9,268)
Contingent consideration	0	(31,266)
Non-cash interest income	0	(2,023)
Operating lease right of use asset amortization	12,749	10,203
Other	107	1,275
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(4,631)	8,315
Inventories	20,131	25,979
Prepaid expenses and other current assets	(2,609)	(12,749)
Other noncurrent assets	484	(707)
Accounts payable	1,780	(8,619)
Accrued liabilities	5,360	(12,514)
Operating lease liabilities	(5,849)	(7,676)
Noncurrent liabilities	(141)	79
Total cash provided by operating activities	136,218	84,853
Cash flows from investing activities:
Acquisitions, net of cash acquired	0	(27,843)
Proceeds from maturity of marketable securities held to maturity	0	102,323
Additions to capitalized software costs	(2,774)	(2,736)
Purchases of property, plant and equipment	(20,137)	(25,135)
Sale of property, plant and equipment	1,290	21
Total cash (used in) provided by investing activities	(21,621)	46,630
Cash flows from financing activities:
Proceeds from exercise of stock options	2,366	356
Payment of tax withholding obligation on vesting of restricted stock	(9,403)	(12,178)
Repayment of Convertible Senior Notes	(69,939)	(33)
Payment of earnout consideration	(7,375)	(7,298)
Other financing activities	0	(13)
Total cash used in financing activities	(84,351)	(19,166)
Effect of exchange rate changes on cash and cash equivalents	2,395	(4,996)
Net increase (decrease) in cash and cash equivalents	32,641	107,321
Cash, cash equivalents and restricted cash, beginning of period	751,323	523,458
Cash and cash equivalents, end of period	783,964	630,779
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	24,087	1,129
Fair value of shares of common stock issued for contingent consideration earnouts	5,742	7,229
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition	$ 0	$ 5,465

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - shares		9 Months Ended
	Apr. 17, 2023	Sep. 30, 2023
FlexBiosys, Inc.
Shares of common stock issued for acquisition	31,415	31,415

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (654)	$ 16,923	$ 8,355	$ 52,046

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false

Restatement of Previously Issue

Restatement of Previously Issued Financial Statements	9 Months Ended
	Sep. 30, 2024
Accounting Changes and Error Corrections [Abstract]
Restatement of Previously Issued Financial Statements	1. Restatement of Previously Issued Financial Statements In the third quarter of 2024, Repligen Corporation (the “Company”, “Repligen”, “our” or “we”) identified a material accounting error related to the timing of revenue recognition which impacts the Company’s condensed consolidated financial statements as of December 31, 2023 and for the three and nine month periods ended September 30, 2023. Within this Quarterly Report on Form 10-Q, the Company has restated all impacted financial information and footnote disclosures impacted by the error. A description of the error and its impact on the previously issued financial statements is included below. Description of restatement adjustments During the first quarter of 2023, a customer cancelled two COVID-related, non-cancellable product purchase orders (“Cancelled PO’s”) in exchange for a $ 17.3 million one-time cash payment (the “Payment”), which the Company received in April 2023. At the time of cancellation, no product units had been delivered under the Cancelled PO’s and the Company had two other open purchase orders from the same customer for the same product (“Open PO’s”). The Company originally accounted for the Cancelled PO’s as a single contract and recognized the $ 17.3 million payment as component of product revenue in the first quarter of 2023. In the third quarter of 2024, the Company reassessed the accounting treatment of the Payment and concluded that the Cancelled PO’s and Open PO’s represented a combined contract such that the February 2023 transaction should have been analyzed and accounted for as a contract modification, which required the Payment to be deferred and recognized as product units were delivered under the Open PO’s ( the "Misstatement"). All Open PO product units were fully delivered to the customer by June 30, 2024. The correction of the error affects certain financial statement line items in both the three and nine month periods ended September 2023 included in these condensed consolidated financial statements, including but not limited to product revenues, income tax provision, foreign currency translation, deferred revenues, prepaid expenses, deferred taxes and earnings-per-share. Consolidated Financial Statements - Restatement Reconciliation Tables The following tables present the impact of the financial statement adjustments on the Company's previously reported condensed consolidated financial statements. The "Previously Reported" amounts in the following tables are amounts derived from our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 22, 2024, and our Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2023, originally filed with the SEC on October 31, 2023. The amounts in the columns labeled "Revenue Adjustments" represent the effect of adjustments resulting from the correction of the overstatement of revenues associated with the Payment and related tax impact. The amounts in the columns labeled "Other Adjustments" represent the effect of other adjustments that relate to other unrelated errors in previously filed financial statements that were not material, individually or in the aggregate, to those filed financial statements. The effects of both the restatement for the Revenue Adjustments and the Other Adjustments have been corrected in all impacted tables and footnotes throughout these condensed consolidated financial statements. December 31, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 751,323 $ — $ — $ 751,323 Marketable securities held to maturity — — — — Accounts receivable, net of reserves of $ 2,122 and $ 1,365 at 124,161 — — 124,161 Inventories, net 202,321 — — 202,321 Prepaid expenses and other current assets 33,238 303 — 33,541 Total current assets 1,111,043 303 — 1,111,346 Noncurrent assets: Property, plant and equipment, net 207,440 — — 207,440 Intangible assets, net 400,486 — 6,471 406,957 Goodwill 987,120 — — 987,120 Deferred tax assets 1,530 — — 1,530 Operating lease right of use assets 115,515 — — 115,515 Other noncurrent assets 1,277 — — 1,277 Total noncurrent assets 1,713,368 — 6,471 1,719,839 Total assets $ 2,824,411 $ 303 $ 6,471 $ 2,831,185 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 19,563 $ — $ — $ 19,563 Operating lease liability 5,631 — — 5,631 Current contingent consideration 12,983 — — 12,983 Accrued liabilities 50,533 6,780 — 57,313 Convertible Senior Notes due 2024, net 69,452 — — 69,452 Total current liabilities 158,162 6,780 — 164,942 Noncurrent liabilities: Convertible Senior Notes due 2028, net 510,143 — — 510,143 Deferred tax liabilities 40,466 ( 903 ) ( 239 ) 39,324 Noncurrent operating lease liability 126,578 — — 126,578 Noncurrent contingent consideration 14,070 — — 14,070 Other noncurrent liabilities 3,789 — 7,494 11,283 Total noncurrent liabilities 695,046 ( 903 ) 7,255 701,398 Total liabilities 853,208 5,877 7,255 866,340 Commitments and contingencies (Note 14) Stockholders' equity: Preferred stock, $ 0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding — — — — Common stock, $ 0.01 par value; 80,000,000 shares authorized; 55,766,078 shares at December 31, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding 558 — — 558 Additional paid-in capital 1,569,227 — — 1,569,227 Accumulated other comprehensive loss ( 37,431 ) ( 377 ) — ( 37,808 ) Accumulated earnings 438,849 ( 5,197 ) ( 784 ) 432,868 Total stockholders’ equity 1,971,203 ( 5,574 ) ( 784 ) 1,964,845 Total liabilities and stockholders’ equity $ 2,824,411 $ 303 $ 6,471 $ 2,831,185 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated Revenue: Products $ 141,156 $ — $ — $ 141,156 $ 482,910 $ ( 17,280 ) $ — $ 465,630 Royalty and other revenue 36 — — 36 111 — — 111 Total revenue 141,192 — — 141,192 483,021 ( 17,280 ) — 465,741 Costs and operating expenses: Cost of product revenue 104,634 — — 104,634 265,786 — — 265,786 Research and development 10,577 — — 10,577 32,437 — — 32,437 Selling, general and administrative 55,465 — 117 55,582 160,601 — 353 160,954 Contingent consideration ( 34,292 ) — — ( 34,292 ) ( 31,266 ) — — ( 31,266 ) Total costs and operating expenses 136,384 — 117 136,501 427,558 — 353 427,911 Income from operations 4,808 — ( 117 ) 4,691 55,463 ( 17,280 ) ( 353 ) 37,830 Other income (expenses): Investment income 6,662 — — 6,662 18,112 — — 18,112 Interest expense ( 269 ) — ( 139 ) ( 408 ) ( 813 ) — ( 414 ) ( 1,227 ) Amortization of debt issuance costs ( 459 ) — — ( 459 ) ( 1,373 ) — — ( 1,373 ) Other income (expenses) 895 — — 895 1,500 — — 1,500 Other income (expenses), net 6,829 — ( 139 ) 6,690 17,426 — ( 414 ) 17,012 Income before income taxes 11,637 — ( 256 ) 11,381 72,889 ( 17,280 ) ( 767 ) 54,842 Income tax (benefit) provision ( 6,535 ) 1,053 ( 60 ) ( 5,542 ) 5,824 ( 2,849 ) ( 179 ) 2,796 Net income $ 18,172 $ ( 1,053 ) $ ( 196 ) $ 16,923 $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Earnings per share: Basic $ 0.33 $ ( 0.02 ) $ ( 0.01 ) $ 0.30 $ 1.20 $ ( 0.26 ) $ ( 0.01 ) $ 0.93 Diluted (Note 13) $ 0.32 $ ( 0.02 ) $ — $ 0.30 $ 1.18 $ ( 0.25 ) $ ( 0.02 ) $ 0.91 Weighted average common shares outstanding: Basic 55,766 — — 55,766 55,688 — — 55,688 Diluted (Note 13) 56,940 — — 56,940 56,933 — — 56,933 Net income $ 18,172 $ ( 1,053 ) $ ( 196 ) $ 16,923 $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Other comprehensive income (loss): Foreign currency translation adjustment ( 6,382 ) 502 — ( 5,880 ) ( 9,177 ) 205 — ( 8,972 ) Comprehensive income $ 11,790 $ ( 551 ) $ ( 196 ) $ 11,043 $ 57,888 $ ( 14,226 ) $ ( 588 ) $ 43,074 Accumulated Other Comprehensive Loss Accumulated Earnings Total Stockholders' Equity As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated $ $ $ $ $ $ $ $ $ $ $ $ Balance at June 30, 2023 ( 37,189 ) ( 297 ) — ( 37,486 ) 446,165 ( 13,378 ) ( 392 ) 432,395 1,970,926 ( 13,675 ) ( 392 ) 1,956,859 Net income — — — — 18,172 ( 1,053 ) ( 196 ) 16,923 18,172 ( 1,053 ) ( 196 ) 16,923 Translation adjustment ( 6,382 ) 502 — ( 5,880 ) — — — — ( 6,382 ) 502 — ( 5,880 ) Balance at September 30, 2023 ( 43,571 ) 205 — ( 43,366 ) 464,337 ( 14,431 ) ( 588 ) 449,318 1,988,557 ( 14,226 ) ( 588 ) 1,973,743 Accumulated Other Comprehensive Loss Accumulated Earnings Total Stockholders' Equity As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated $ $ $ $ $ $ $ $ $ $ $ $ Balance at December 31, 2022 ( 34,394 ) — — ( 34,394 ) 397,272 — — 397,272 1,910,700 — — 1,910,700 Net income — — — — 67,065 ( 14,431 ) ( 588 ) 52,046 67,065 ( 14,431 ) ( 588 ) 52,046 Translation adjustment ( 9,177 ) 205 — ( 8,972 ) — — — — ( 9,177 ) 205 — ( 8,972 ) Balance at September 30, 2023 ( 43,571 ) 205 — ( 43,366 ) 464,337 ( 14,431 ) ( 588 ) 449,318 1,988,557 ( 14,226 ) ( 588 ) 1,973,743 Nine Months Ended September 30, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated Cash flows from operating activities: Net income $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 50,942 — 353 51,295 Amortization of debt issuance costs 1,373 — — 1,373 Stock-based compensation 19,110 — — 19,110 Deferred income taxes, net ( 9,756 ) 667 ( 179 ) ( 9,268 ) Contingent consideration ( 31,266 ) — — ( 31,266 ) Non-cash interest income ( 2,023 ) — — ( 2,023 ) Operating lease right of use asset amortization 10,203 — — 10,203 Other 861 — 414 1,275 Changes in operating assets and liabilities, excluding impact of acquisitions: Accounts receivable 8,315 — — 8,315 Inventories 25,979 — — 25,979 Prepaid expenses and other assets ( 10,733 ) ( 2,016 ) — ( 12,749 ) Other assets ( 707 ) — — ( 707 ) Accounts payable ( 8,619 ) — — ( 8,619 ) Accrued expenses ( 28,294 ) 15,780 — ( 12,514 ) Operating lease liabilities ( 7,676 ) — — ( 7,676 ) Long-term liabilities 79 — — 79 Total cash provided by operating activities 84,853 — — 84,853 Cash flows from investing activities: Acquisitions, net of cash acquired ( 27,843 ) — — ( 27,843 ) Proceeds from maturity of marketable securities held to maturity 102,323 — — 102,323 Additions to capitalized software costs ( 2,736 ) — — ( 2,736 ) Purchases of property, plant and equipment ( 25,135 ) — — ( 25,135 ) Purchase of intellectual property — — — — Other investing activities 21 — — 21 Total cash provided by (used in) investing activities 46,630 — — 46,630 Cash flows from financing activities: Proceeds from exercise of stock options 356 — — 356 Payment of tax withholding obligation on vesting of restricted stock ( 12,178 ) — — ( 12,178 ) Repayment of Convertible Senior Notes ( 33 ) — — ( 33 ) Payment of earnout consideration ( 7,298 ) — — ( 7,298 ) Proceeds from issuance of common stock, net ( 13 ) — — ( 13 ) Total cash used in financing activities ( 19,166 ) — — ( 19,166 ) Effect of exchange rate changes on cash and cash equivalents ( 4,996 ) — — ( 4,996 ) Net increase (decrease) in cash and cash equivalents 107,321 — — 107,321 Cash, cash equivalents and restricted cash, beginning of period 523,458 — — 523,458 Cash and cash equivalents, end of period $ 630,779 $ — $ — $ 630,779 Supplemental disclosure of non-cash investing and financing activities: Assets acquired under operating leases $ 1,129 $ — $ — $ 1,129 Fair value of 31,415 shares of common stock issued for the acquisition of $ 5,465 $ — $ — $ 5,465 Fair value of 42,621 shares of common stock issued for the Avitide, Inc. $ 7,229 $ — $ — $ 7,229

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated interim financial statements included herein have been prepared by Repligen Corporation in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP in annual financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023, which was filed with the SEC on November 18, 2024 (“Form 10-K/A”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The business and economic uncertainty resulting from global geopolitical conflicts, supply chain challenges and cost pressures on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K/A. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of its financial position as of September 30, 2024, its results of operations for the three and nine months ended September 30, 2024 and 2023 and cash flows for the nine months ended September 30, 2024 and 2023 . The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. Assets Held for Sale An asset is considered to be held for sale when all the following criteria are met: (i) management commits to a plan to sell the asset; (ii) it is unlikely that the disposal plan will be significantly modified or discontinued; (iii) the asset is available for immediate sale in its present condition; (iv) actions required to complete the sale of the asset have been initiated; (v) sale of the asset is probable and the completed sale is expected to occur within one year; and (vi) the asset is actively being marketed for sale at a price that is reasonable given its current market value. Convertible Instruments The Company evaluates the embedded conversion feature within its convertible debt instruments under Accounting Standards Codification (“ASC”) 815, ”Derivatives and Hedging.” The Company refers to ASC 815-15 and ASC 815-40 to determine if the conversion feature meets the definition of a derivative and, if so, whether to bifurcate the conversion feature and account for it as a separate derivative liability. Based on the Company’s analysis, its Convertible Senior Notes do not have an embedded conversion feature requiring bifurcation under ASC 815-15 and thus are accounted for as a single unit of account, a liability under ASC 470, “ Debt.” Recent Accounting Guidance The Company considers the applicability and impact of all Accounting Standards Updates (“ASU” or “ASUs”) and other recently issued guidance or rule decisions on their condensed consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial position or results of operations. Recently issued accounting guidance that the Company believes may be applicable to them is as follows: Recently Issued Accounting Guidance – Not Yet Adopted In March 2024, the SEC adopted final rules under SEC Release No. 33-11275 requiring public companies to provide certain climate-related information in their registration statements and annual reports. As part of the disclosures, registrants will be required to quantify certain effects of severe weather events and other natural conditions in a note to their audited financial statements. The rules were immediately challenged in a number of lawsuits, which were subsequently consolidated by the U.S. Court of Appeals for the Eighth Circuit. In April 2024, the SEC announced that it is staying implementation of the new rules pending resolution of the consolidated litigation before the Eighth Circuit. The Company is assessing the effect of compliance with the new rules on its condensed consolidated financial statements and related disclosures. In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “ Income Taxes (Topic 740) - Improvements to Income Tax Disclosures.” ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax disclosure included in its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application is permitted. Early adoption is also permitted. Besides a change in income tax disclosures, the Company does not expect the adoption of ASU 2023-09 to have a material impact on its condensed consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, “S egment Reporting (Topic 820) - Improvements to Reportable Segment Disclosures.” ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced annual and interim disclosures about significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”). The disclosures required under ASU 2023-07 are also required for public entities with a single reportable segment. ASU 2023-07 will be effective for the Company for annual periods beginning on January 1, 2024 and interim periods beginning on January 1, 2025. The amendments of this guidance apply retrospectively to all prior periods presented. Early adoption is permitted. Besides a change in presentation in the segment footnote, the Company does not expect the adoption of ASU 2023-07 to have a material impact on its condensed consolidated financial statements.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Disclosure Text Block [Abstract]
Fair Value Measurements	3. Fair Value Measurements The Company uses various valuation approaches in determining the fair value of its assets and liabilities. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 - Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities. Level 3 - Valuations based on inputs that are unobservable or significant to the overall fair value measurement. The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. Fair Value Measured on a Recurring Basis Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 30, 2024 and December 31, 2023 (amounts in thousands): As of September 30, 2024 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 669,347 $ — $ — $ 669,347 Liabilities: Current contingent consideration $ — $ — $ 13,936 $ 13,936 As of December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 658,574 $ — $ — $ 658,574 Liabilities: Current contingent consideration $ — $ — $ 12,983 $ 12,983 Noncurrent contingent consideration $ — $ — $ 14,070 $ 14,070 Cash and cash equivalents As of September 30, 2024 and December 31, 2023, cash and cash equivalents on the Company's condensed consolidated balance sheets included $ 669.3 million and $ 658.6 million, respectively, in money market accounts. These funds are valued on a recurring basis using Level 1 inputs. Contingent Consideration – Earnouts As of September 30, 2024 , the maximum amount of future contingent consideration (undiscounted) that we could be required to pay in connection with completed acquisitions is: $ 125.0 million over a three-year earnout period for Avitide, Inc. (“Avitide”), which was acquired in September 2021 and for which the earnout periods run from January 1, 2022 through December 31, 2024; $ 42.0 million over a two-year earnout period for FlexBiosys, Inc. (“FlexBiosys”), which was acquired in April 2023 and for which the earnout periods run from January 1, 2023 through December 31, 2024; and approximately $ 10 million over a one-year earnout period for Metenova Holding AB (“Metenova”), which was acquired in October 2023 and for which the earnout period runs from January 1, 2024 through December 31, 2024. See Note 4, “ Acquisitions” to this report for additional information on the contingent consideration earnouts. Since the date of acquisition, expected results and changes in market inputs used to calculate the discount rate related to Avitide, FlexBiosys and Metenova, have, at times, resulted in changes in amounts reported as the Company’s contingent consideration obligation. As of September 30, 2024, management assessed the remaining contingent consideration obligation balances and the existing market inputs used and decided that no changes in fair value were required. A reconciliation of the change in the fair value of contingent consideration – earnouts is included in the following table (amounts in thousands): Balance at December 31, 2023 $ 27,053 Payment of contingent consideration earnouts ( 13,117 ) Decrease in fair value of contingent consideration earnouts — Balance at September 30, 2024 $ 13,936 The recurring Level 3 fair value measurement of our contingent consideration obligations for Avitide, FlexBiosys and Metenova include the following significant unobservable inputs (amounts in thousands, except percent data): Contingent Consideration Earnout Fair Value as of Valuation Technique Unobservable Input Range Weighted Average (1) Probability of Success 100 % 100 % Commercialization-based payments $ 9,678 Monte Carlo Earnout Discount Rate 5.8 %- 5.9 % 5.9 % Volatility 12.5 %- 24.6 % 13.9 % Revenue and Volume- $ 361 Monte Carlo Revenue & Volume 2.5 %- 9.3 % 5.1 % Earnout Discount Rate 5.8 %- 7.2 % 5.8 % Probability of 100 % 100 % Manufacturing line expansions $ 3,897 Probability-weighted present value Earnout Discount Rate 6.1 %- 6.4 % 6.3 % (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. Fair Value Measured on a Nonrecurring Basis During the three and nine months ended September 30, 2024, there were no re-measurements to the fair value of financial assets and liabilities that are measured at fair value on a nonrecurring basis. Convertible Senior Notes In July 2019, the Company issued $ 287.5 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “2019 Notes”), which matured and were paid in July 2024. At December 31, 2023, the carrying value of the 2019 Notes was $ 69.5 million, net of unamortized debt issuance costs and the fair value of the 2019 Notes was $ 109.8 million using a Level 1 valuation and determined based on the most recent trade activity of the 2019 Notes as of December 31, 2023. On December 14, 2023, the Company issued $ 600.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “2023 Notes”) in a private placement pursuant to separate, privately negotiated exchange and subscription agreements (the “Exchange and Subscription Agreements”) with a limited number of holders of its outstanding 2019 Notes and certain other qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (“Securities Act”). Pursuant to the Exchange and Subscription Agreements, the Company exchanged $ 217.7 million of its 2019 Notes for $ 309.9 million aggregate principal amount of the 2023 Notes (the “Exchange Transaction”) and issued $ 290.1 million aggregate principal amount of the 2023 Notes (the “Subscription Transactions”) for $ 290.1 million in cash. At September 30, 2024 and December 31, 2023, the carrying value of the 2023 Notes was $ 521.6 million and $ 510.1 million, respectively, net of unamortized debt discount and debt issuance cost and the fair value of the 2023 Notes was $ 553.3 million and $ 596.0 million, respectively. The fair value of the 2023 Notes is a Level 1 valuation and was determined based on the most recent trade activity of the 2023 Notes as of September 30, 2024 and December 31, 2023. The 2023 Notes and 2019 Notes are discussed in more detail in Note 9, “ Convertible Senior Notes,” to these condensed consolidated financial statements.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions	4. Acquisitions 2024 Acquisition Pending Acquisition of Tantti Laboratory Inc. On July 29, 2024, the Company announced that it entered into a definitive agreement to acquire privately-held Tantti Laboratory Inc. (“Tantti”). Tantti, which is headquartered in Taoyuan City, Taiwan, is expected to accelerate the Company’s expansion into new modality markets with unique, scalable purification solutions for large molecule biologics. The Company expects the acquisition of Tantti to be completed in the fourth quarter of 2024 subject to the satisfaction of customary closing conditions, including clearance through the Taiwanese regulatory channel. 2023 Acquisitions Metenova Holding AB On October 2, 2023, the Company's subsidiary, Repligen Sweden AB, acquired Metenova from the former shareholders of Metenova (the “Metenova Seller”) pursuant to a Share Sale and Purchase Agreement (the “Share Purchase Agreement”), dated as of September 23, 2023 (such acquisition, the “Metenova Acquisition”), by and among Repligen Sweden AB, the Metenova Seller, and the Company, in its capacity as guarantor of the obligations of Repligen Sweden AB under the Share Purchase Agreement. Metenova, which is headquartered in Molndal, Sweden, offers magnetic mixing and drive train technologies that are widely used by global biopharmaceutical companies and contract development and manufacturing organizations. The Metenova Acquisition further strengthens our fluid management portfolio with these products. Consideration Transferred The Company accounted for the Metenova Acquisition as a purchase of business under ASC 805, “ Business Combinations,” and the Company engaged a third-party valuation firm to assist with the valuation of Metenova. Under the Share Purchase Agreement, all outstanding equity interests of Metenova were acquired for consideration with a value totaling $ 172.6 million. The Metenova Acquisition was funded through payment of $ 164.5 million in cash, the issuance of 52,299 unregistered shares of the Company's common stock totaling $ 8.1 million and contingent consideration with an immaterial fair value. Under the acquisition method of accounting, the assets acquired and liabilities assumed of Metenova were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net liabilities acquired is $ 1.9 million, the fair value of the intangible assets acquired is $ 58.8 million and the residual goodwill is $ 115.7 million. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company has incurred $ 6.5 million of transaction and integration costs associated with the Metenova Acquisition from the date of acquisition to September 30, 2024, wit h $ 0.4 million and $ 3.0 million o f transaction and integration costs incurred during the three and nine months ended September 30, 2024, respectively. The transaction costs are included in operating expenses in the condensed consolidated statements of comprehensive income (loss) for the period ended September 30, 2024. Fair Value of Net Assets Acquired The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed based on the final valuation of Metenova. The Company has made appropriate adjustments to the purchase price allocation during the measurement period, which ended on October 2, 2024. The components and final allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 5,768 Accounts receivable 3,730 Inventory 4,477 Prepaid expenses and other current assets 470 Property and equipment 433 Operating lease right of use asset 615 Customer relationships 12,659 Developed technology 44,377 Trademark and tradename 939 Non-competition agreements 787 Goodwill 115,722 Accounts payable ( 1,432 ) Accrued liabilities ( 2,934 ) Operating lease liability ( 275 ) Noncurrent deferred tax liability ( 12,481 ) Noncurrent operating lease liability ( 255 ) Fair value of net assets acquired $ 172,600 Acquired Goodwill The goodwill of $ 115.7 million represents future economic benefits expected to arise from anticipated synergies from the integration of Metenova into the Company. These synergies include operating efficiencies and strategic benefits projected to be achieved as a result of the Metenova Acquisition. Substantially all of the goodwill recorded is expected to be nondeductible for income tax purposes. Intangible Assets The following table sets forth the components of the identified intangible assets associated with the Metenova Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 15 years $ 12,659 Developed technology 15 years 44,377 Trademark and tradename 15 years 939 Non-competition agreements 2 years 787 $ 58,762 FlexBiosys, Inc. On April 17, 2023 , the Company completed its acquisition of all of the outstanding equity interests in FlexBiosys, pursuant to an Equity Purchase Agreement (the “FlexBiosys Agreement”) with FlexBiosys, TSAP Holdings Inc. (“NJ Seller”), Gayle Tarry and Stanley Tarry, as individuals (collectively with NJ Seller, the "Sellers"), and Stanley Tarry, in his capacity as the representative of the Sellers (the “FlexBiosys Acquisition”). FlexBiosys, which is headquartered in Branchburg, New Jersey, offers expert design and custom manufacturing of single-use bioprocessing products and a comprehensive range of products that include bioprocessing bags, bottles, and tubing assemblies. These products will complement and expand our fluid management portfolio of offerings. Consideration transferred The FlexBiosys Acquisition was accounted for as a purchase of a business under ASC 805, and the Company engaged a third-party valuation firm to assist with the valuation of FlexBiosys. Under the terms of the FlexBiosys Agreement, all outstanding equity interests of FlexBiosys were acquired for consideration with a value totaling $ 41.0 million. The FlexBiosys Acquisition was funded through payment of $ 29.0 million in cash, which includes $ 6.3 million deposited in escrow for future payments, the issuance of 31,415 unregistered shares of the Company's common stock totaling $ 5.4 million and contingent consideration with fair value of approximately $ 6.6 million. Under the acquisition method of accounting, the assets acquired and liabilities assumed of FlexBiosys were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired is $ 14.1 million, the fair value of the intangible assets acquired is $ 12.6 million and the residual goodwill is $ 14.3 million. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company has incurred $ 1.1 million of transaction and integration costs associated with the FlexBiosys Acquisition from the date of acquisition to September 30, 2024. There were no transaction and integration costs incurred for the FlexBiosys Acquisition during the three and nine months ended September 30, 2024. Fair Value of Net Assets Acquired The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the final valuation of FlexBiosys. The Company has made appropriate adjustments to the purchase price allocation during the measurement period, which ended on April 17, 2024. The purchase price allocation was completed as of March 31, 2024. The components and final allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 1,090 Accounts receivable 683 Inventory 667 Prepaid expenses and other current assets 35 Property and equipment 12,034 Operating lease right of use asset 3,537 Customer relationships 2,530 Developed technology 9,860 Trademark and tradename 30 Non-competition agreements 220 Goodwill 14,321 Other noncurrent assets 10 Accounts payable ( 136 ) Accrued liabilities ( 314 ) Operating lease liability ( 39 ) Noncurrent operating lease liability ( 3,498 ) Fair value of net assets acquired $ 41,030 Acquired Goodwill The goodwill of $ 14.3 million represents future economic benefits expected to arise from anticipated synergies from the integration of FlexBiosys into the Company. These synergies include operating efficiencies and strategic benefits projected to be achieved as a result of the FlexBiosys Acquisition. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes. Intangible Assets The following table sets forth the components of the identified intangible assets associated with the FlexBiosys Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 12 years $ 2,530 Developed technology 16 years 9,860 Trademark and tradename 4 years 30 Non-competition agreements 5 years 220 $ 12,640

Restructuring Plan

Restructuring Plan	9 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring Plan	5. Restructuring Plan In July 2023, the Board of Directors authorized the Company's management team to undertake restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations. Since the initial streamlining and re-balancing efforts contemplated in July, the Company continues to undertake further restructuring activities (collectively, the “2023 Restructuring Plan”) which has included consolidating a portion of our manufacturing operations between certain U.S. locations, discontinuing the sale of certain product SKUs, and evaluating the fair value of finished goods and raw materials, mostly secured during the 2020-2022 COVID-19 pandemic period (the “COVID-19 Period”) to meet increasing demand during a challenging supply chain environment in the industry. The Company recorded pre-tax restructuring activity of $ 2.9 million and $ 5.3 million , respectively, for the three and nine months ended September 30, 2024, and $ 24.0 million for the three and nine months ended September 30, 2023, related to the 2023 Restructuring Plan, which the Company expects to complete during the fourth quarter of 2024. The following tables summarize the charges related to restructuring activities by type of cost for the periods presented on the Company’s condensed consolidated statements of comprehensive income (loss): Three Months Ended September 30, 2024 Severance and Employee-Related Costs Facility and Other Exit Costs Total (Amounts in thousands) Cost of goods sold $ 23 $ 1,461 $ 1,484 Selling, general and administrative 631 1,037 1,668 Other (income) expenses — ( 234 ) ( 234 ) $ 654 $ 2,264 $ 2,918 Nine Months Ended September 30, 2024 Severance and Employee-Related Costs Accelerated Depreciation Facility and Other Exit Costs Total (Amounts in thousands) Cost of goods sold $ 876 $ 19 $ 1,661 $ 2,556 Research and development 449 — — 449 Selling, general and administrative 1,486 — 1,054 2,540 Other (income) expenses — — ( 234 ) ( 234 ) $ 2,811 $ 19 $ 2,481 $ 5,311 Three and Nine Months Ended September 30, 2023 Severance and Employee-Related Costs Inventory Write-Off Accelerated Depreciation Facility and Other Exit Costs Total (Amounts in thousands) Cost of goods sold $ 1,654 $ 17,185 $ 3,788 $ 84 $ 22,711 Research and development 34 — 1 — 35 Selling, general and administrative 1,142 — 27 97 1,266 $ 2,830 $ 17,185 $ 3,816 $ 181 $ 24,012 Severance and employee-related costs under the Restructuring Plan are primarily associated with actual headcount reductions. Costs incurred include cash severance and non-cash severance, including other termination benefits. Severance and other termination benefit packages are based on established benefit arrangements or local statutory requirements and we recognized the contractual component of these benefits when payment was probable and could be reasonably estimated. The inventory write-off in 2023 includes the impact of the Company discontinuing the sale of certain product SKUs and the impact of having proactively secured materials during the COVID-19 Period to meet accelerated demand during a challenging supply chain environment in the industry. Where demand has reduced, finished goods and raw materials, the value of which exceeded the projected requirements to be used before reaching their expiration date, were written down to their realizable value. The 2023 Restructuring Plan also includes the closing of manufacturing facilities and production lines, which include inventory that could not be re-purposed. Non-cash charges for accelerated depreciation were recognized on long-lived assets that were taken out of service before the end of their normal service due to the shutdown of manufacturing facilities and production lines, in which case depreciation estimates were revised to reflect the use of the assets over their shortened useful life. The restructuring accrual is included in accrued liabilities in the condensed consolidated balance sheet as of September 30, 2024. Activity related to the Restructuring Plan for the nine months ended September 30, 2024 was as follows (amounts in thousands): Restructuring Liability Restructuring Costs Amounts Paid in 2024 Noncash Restructuring Items Restructuring Liability Severance & employee-related costs $ 464 $ 2,811 $ ( 3,030 ) $ ( 49 ) $ 196 Accelerated depreciation — 19 — ( 19 ) — Facility and other exit costs — 2,481 ( 2,715 ) 234 — Total $ 464 $ 5,311 $ ( 5,745 ) $ 166 $ 196

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Revenue Recognition	6. Revenue Recognition Disaggregation of Revenue Revenues for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (Amounts in thousands) (As Restated) Product revenue $ 154,834 $ 141,156 $ 466,784 $ 465,630 Royalty and other income 37 36 108 111 Total revenue $ 154,871 $ 141,192 $ 466,892 $ 465,741 When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, factors such as regulatory, economic and geopolitical developments within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Disaggregated revenue from contracts with customers by geographic region and revenue from significant customers can be found in Note 15, “Segment Reporting,” included in this report. For more information regarding our product revenue, see Note 8, “Revenue Recognition” included in Part II, Item 8, “ Financial Statements and Supplementary Data” to the Company’s Form 10-K/A. Contract Balances from Contracts with Customers The following table provides information about receivables and deferred revenue from contracts with customers as of September 30, 2024 and December 31, 2023 (amounts in thousands): September 30, December 31, 2024 2023 (As Restated) Balances from contracts with customers only: Accounts receivable $ 129,026 $ 124,161 Deferred revenue (included in accrued liabilities and $ 16,884 $ 17,536 Revenue recognized during periods presented relating to: The beginning deferred revenue balance $ 15,365 $ 18,751 The timing of revenue recognition, billings and cash collections results in the accounts receivable and deferred revenue balances on the Company’s condensed consolidated balance sheets.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2024
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets Goodwill The following table represents the change in the carrying value of goodwill for the nine months ended September 30, 2024 (amounts in thousands): Balance at December 31, 2023 $ 987,120 Measurement period adjustment - Metenova ( 56 ) Cumulative translation adjustment 556 Balance at September 30, 2024 $ 987,620 The Company has not identified any “triggering” events which indicate an impairment of goodwill in the three and nine months ended September 30, 2024. Intangible assets (As Restated) Indefinite-lived intangible assets are reviewed for impairment at least annually. There has been no impairment of the Company’s intangible assets for the periods presented. Intangible assets, net, consisted of the following at September 30, 2024: September 30, 2024 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology – developed $ 256,482 $ ( 56,803 ) $ 199,679 16 Patents 240 ( 240 ) — 8 Customer relationships 270,049 ( 97,210 ) 172,839 15 Trademarks 8,757 ( 2,183 ) 6,574 19 Other intangibles 3,917 ( 2,955 ) 962 3 Total finite-lived intangible assets 539,445 ( 159,391 ) 380,054 15 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 540,145 $ ( 159,391 ) $ 380,754 Intangible assets, net, consisted of the following at December 31, 2023: December 31, 2023 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: (As Restated) (As Restated) (As Restated) Technology – developed $ 256,536 $ ( 44,633 ) $ 211,903 16 Patents 240 ( 240 ) — 8 Customer relationships 269,949 ( 83,963 ) 185,986 15 Trademarks 8,757 ( 1,789 ) 6,968 19 Other intangibles 3,914 ( 2,514 ) 1,400 3 Total finite-lived intangible assets 539,396 ( 133,139 ) 406,257 15 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 540,096 $ ( 133,139 ) $ 406,957 Amortization expense for finite-lived intangible assets was $ 8.6 million and $ 7.6 million for each of the three months ended September 30, 2024 and 2023, respectively, and $ 26.0 million and $ 22.8 million for each of the nine months ended September 30, 2024 and 2023 , respectively. As of September 30, 2024, the Company expects to record the following amortization expense in future periods (amounts in thousands): Estimated Amortization For the Years Ended December 31, Expense 2024 (remaining three months) $ 8,620 2025 34,354 2026 34,000 2027 33,965 2028 33,863 2029 and thereafter 235,252 Total $ 380,054

Consolidated Balance Sheet Deta

Consolidated Balance Sheet Detail	9 Months Ended
	Sep. 30, 2024
Disclosure Text Block [Abstract]
Consolidated Balance Sheet Detail	8. Consolidated Balance Sheet Detail Inventories, net Inventories, net consists of the following: September 30, December 31, 2024 2023 (Amounts in thousands) Raw materials $ 106,843 $ 123,598 Work-in-process 6,794 4,492 Finished products 68,828 74,231 Total inventories, net $ 182,465 $ 202,321 Assets held for sale During the first quarter of 2024, the Company’s management decided it would explore a sale of the Company’s property located at 119 Fredon Springdale Road, Fredon, New Jersey (the “BioFlex Property”) and engaged a broker to assist with the sale process. As a result of these actions, the Company determined that the sale of the BioFlex Property met the criteria to be classified as assets held-for-sale pursuant to ASC 360, “ Impairment and Disposal of Long-Lived Assets” beginning in the first quarter of 2024. The Company recorded $ 1.0 million in assets held for sale in our condensed consolidated balance sheet at the end of the first and second quarters of 2024. The sale of the BioFlex Property closed on August 2, 2024 and the Company recorded a gain of $ 0.2 million on the sale of the BioFlex Property to its condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2024. Property, plant and equipment, net Property, plant and equipment, net consist of the following: September 30, December 31, 2024 2023 (Amounts in thousands) Land $ 893 $ 992 Buildings 725 1,667 Leasehold improvements 142,506 126,663 Equipment 120,029 114,606 Furniture, fixtures and office equipment 10,035 9,077 Computer hardware and software 40,790 35,528 Construction in progress 40,241 47,086 Other 488 544 Total property, plant and equipment 355,707 336,163 Less - Accumulated depreciation ( 153,124 ) ( 128,723 ) Total property, plant and equipment, net $ 202,583 $ 207,440 Accrued liabilities Accrued liabilities consist of the following: September 30, December 31, 2024 2023 (Amounts in thousands) (As Restated) Employee compensation $ 28,104 $ 16,660 Deferred revenue 16,446 17,067 Income taxes payable 148 6,814 Other 16,204 16,772 Total accrued liabilities $ 60,902 $ 57,313

Convertible Senior Notes

Convertible Senior Notes	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Convertible Senior Notes	9. Convertible Senior Notes The carrying value of the Company's Convertible Senior Notes is as follows: September 30, December 31, (Amounts in thousands) 1.00% Convertible Senior Notes due 2028: Principal amount $ 600,000 $ 600,000 Unamortized debt discount ( 71,261 ) ( 81,457 ) Unamortized debt issuance costs ( 7,132 ) ( 8,400 ) Carrying amount - Convertible Senior Notes due 2028, net $ 521,607 $ 510,143 0.375% Convertible Senior Notes due 2024: Principal amount $ — $ 69,700 Unamortized debt issuance costs — ( 248 ) Carrying amount - Convertible Senior Notes due 2024, net $ — $ 69,452 1.00% Convertible Senior Notes due 2028 On December 14, 2023, the Company issued $ 600.0 million aggregate principal amount of its 2023 Notes in the Exchange and Subscription Agreements with a limited number of holders of its outstanding 2019 Notes and certain other qualified institutional buyers pursuant to Rule 144A under the Securities Act. Pursuant to the Exchange and Subscription Agreements and to the Exchange Transaction, the Company issued $ 290.1 million aggregate principal amount of the 2023 Notes in a private placement to accredited institutional buyers (the “Subscription Transactions”) for $ 290.1 million in cash. The Company evaluated the Exchange Transaction and determined approximately $ 29.6 million of the $ 217.7 million principal of the exchanged 2019 Notes should be accounted for as extinguishments of debt and approximately $ 188.1 million should be accounted for as modification of debt. As a result, the Company recognized a $ 12.7 million loss on extinguishments of debt in its consolidated statements of comprehensive income (loss) for the year ended December 31, 2023, inclusive of $ 0.1 million of unamortized debt issuance costs. Under debt modification accounting, the carrying amount of the modified 2019 Notes was reduced by $ 2.8 million, with a corresponding increase to additional paid-in capital, to account for the increase in the fair value of the embedded conversion option, representing a debt discount of the modified 2019 Notes. The aggregate debt discount of $ 71.3 million as of September 30, 2024, comprised of $ 68.9 million increase in principal of the modified 2019 Notes and a $ 2.4 million increase in the fair value of the embedded conversion option. The aggregate debt discount of $ 81.5 million as of December 31, 2023, comprised of $ 78.7 million increase in principal of the modified 2019 Notes and a $ 2.8 million increase in the fair value of the embedded conversion option. These amounts are presented as a direct reduction from the carrying value of the convertible debt in their respective periods presented in our condensed consolidated balance sheets. This amount is being accreted into interest expense in the condensed consolidated statements of comprehensive income (loss) using the effective interest method over the term of the 2023 Notes. Proceeds from the Subscription Transactions were $ 276.1 million, net of debt issuance costs of $ 13.9 million. The Exchange Transaction resulted in $ 6.2 million of the debt issuance costs related to the modified 2019 Notes, which were expensed as incurred in accordance with debt modification accounting, and $ 7.7 million of deferred debt issuance costs related to the 2023 Notes, which were recorded as a direct deduction to the carrying value of the 2023 Notes on the Company’s condensed consolidated balance sheets. The Company is amortizing the $ 7.7 million of debt issuance costs of the 2023 Notes into amortization of debt issuance costs in the Company’s condensed consolidated statements of comprehensive income (loss) over the remaining term of the 2023 Notes. The carrying value of the 2023 Notes of $ 521.6 million and $ 510.1 million is included in long-term debt on the Company's condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively. The Company used $ 14.4 million of the proceeds from the Subscription Transactions to repurchase shares of its common stock from certain purchasers of the 2023 Notes. For more information regarding this repurchase, see Note 13, “Stockholders’ Equity - Share Repurchases” included in Part II, Item 8, “ Financial Statements and Supplementary Data,” to the Company's Form 10-K/A. The Company also used a portion of the proceeds to finance in part, the settlement upon redemption of the remaining 2019 Notes at maturity. The remainder of the proceeds will be used for working capital. The 2023 Notes are senior, unsecured obligations of the Company, and bear interest at a rate of 1.00 % per year. Interest is payable semi-annually in arrears on each of June 15 and December 15, which commenced on June 15, 2024 . The 2023 Notes will mature on December 15, 2028 , unless earlier redeemed, repurchased or converted. During the third quarter of 2024, the closing price of the Company’s common stock did not exceed 130 % of the conversion price of the 2023 Notes for more than 20 trading days of the last 30 consecutive trading of the quarter. As a result, the 2023 Notes are not convertible at the option of the holders of the 2023 Notes during the fourth quarter of 2024, the quarter immediately following the quarter when the conditions are met, as stated in the indenture governing the 2023 Notes. Because the 2023 Notes were not convertible as of September 30, 2024, the Company continues to classify the carrying value of the 2023 Notes of $ 521.6 million as noncurrent liabilities on the Company’s condensed consolidated balance sheet at September 30, 2024. The initial conversion rate for the 2023 Notes is 4.9247 shares of the Company’s common stock per $ 1,000 principal amount of 2023 Notes, which is equivalent to an initial conversion price of $ 203.06 per share and represents a 30 % premium over the last reported sale price of $ 156.20 per share on December 6, 2023, the date on which the 2023 Notes were priced. Prior to the close of business on the business day immediately preceding September 15, 2028, the 2023 Notes will be convertible at the option of the holders of 2023 Notes only upon the satisfaction of the specified conditions mentioned above and during certain quarters commencing after the calendar quarter ending on March 31, 2024, into cash up to their principal amount, and into cash, shares of the Company’s common stock or a combination thereof, at the Company’s election, for the conversion value above the principal amount, if any. Thereafter until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2023 Notes will be convertible at the option of the holders of 2023 Notes at any time regardless of these conditions. The Company may redeem for cash, all or a portion of the 2023 Notes, at its option, on or after December 18, 2026 and prior to the 21 st scheduled trading day immediately preceding the maturity date at a redemption price of 100 % of the principal amount of the 2023 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date, if certain conditions are met in accordance to the 2023 Notes Indenture. For more information on the 2023 Notes, see Note 15, “ Convertible Senior Notes,” included in Part II, Item 8, “ Financial Statements and Supplementary Data,” to the Company’s Form 10-K/A. The following table sets forth total interest expense recognized related to the 2023 Notes for the three and nine months ended September 30, 2024 for which there were no comparable amounts for the same periods of 2023: Three Months Ended Nine Months Ended 2024 2024 (Amounts in thousands, except percentage data) Contractual interest expense – 2023 Notes $ 1,500 $ 4,500 Amortization of debt discount – 2023 Notes 3,473 10,197 Amortization of debt issuance costs – 2023 Notes 410 1,190 Total $ 5,383 $ 15,887 Effective interest rate of the liability component 4.39 % 4.39 % At September 30, 2024 and December 31, 2023, the carrying value of the 2023 Notes was $ 521.6 million and $ 510.1 million, respectively, net of unamortized discount, and the fair value of the 2023 Notes was $ 553.3 million and $ 596.0 million, respectively. The fair value of the 2023 Notes was determined based on the most recent trade activity of the 2023 Notes at September 30, 2024 and December 31, 2023. 0.375% Convertible Senior Notes due 2024 The Company issued $ 287.5 million aggregate principal amount of the 2019 Notes on July 19, 2019 in a transaction which included the underwriters’ exercise in full of an option to purchase an additional $ 37.5 million aggregate principal amount of the 2019 Notes (the “Notes Offering”). The net proceeds of the Notes Offering, after deducting underwriting discounts and commissions and other related offering expenses payable by the Company, were approximately $ 278.5 million. Immediately following the closing of the Exchange Transaction mentioned above, $ 69.7 million in aggregate principal amount of the 2019 Notes remained outstanding as of December 31, 2023. During 2024, $ 0.2 million aggregate principal amount of the 2019 Notes converted, bringing the remaining outstanding 2019 Notes to $ 69.5 million in aggregate principal amount. The remaining 2019 Notes matured and were paid off in full on July 15, 2024. As mentioned above, the Company used net proceeds from the Exchange Transaction to fund the repayment of the 2019 Notes at maturity and to pay accrued and unpaid interest with respect to such notes. The Company irrevocably elected to settle the conversion of the 2019 Notes using a combination of cash and the Company’s common stock, settling the par value of the 2019 Notes in cash and any excess conversion premium in shares. In connection with the conversion, the Company paid $ 69.6 million in cash, which included principal and accrued interest, and issued 100,942 shares of the Company’s common stock representing the conversion premium. For more information on the 2023 Notes, see Note 15, “ Convertible Senior Notes,” included in Part II, Item 8, “ Financial Statements and Supplementary Data,” to the Company’s Form 10-K/A. The following table sets forth total interest expense recognized related to the 2019 Notes: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (Amounts in thousands, except percentage data) Contractual interest expense – 2019 Notes $ 11 $ 269 $ 141 $ 808 Amortization of debt issuance costs – 2019 Notes 19 459 243 1,373 Total $ 30 $ 728 $ 384 $ 2,181 Effective interest rate of the liability component 1.00 % 1.00 % 1.00 % 1.00 % At December 31, 2023 , the carrying value of the 2019 Notes was $ 69.5 million, net of unamortized discount, and the fair value of the 2019 Notes was $ 109.8 million. The fair value of the 2019 Notes was determined based on the most recent trade activity of the 2019 Notes at December 31, 2023 .

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Stock Option and Incentive Plans Under the Company’s current 2018 Stock Option and Incentive Plan (the “2018 Plan”), the number of shares of the Company’s common stock that were reserved and available for issuance is 2,778,000 , plus the number of shares of common stock that were available for issuance under the Company’s previous equity plans. The shares of common stock underlying any awards under the 2018 Plan and previous equity plans (together, the “Plans”) that are forfeited, canceled or otherwise terminated (other than by exercise) shall be added back to the shares of stock available for issuance under the 2018 Plan. At September 30, 2024, 1,487,289 shares were available for future grants under the 2018 Plan. Former Chief Executive Officer Accounting Modifications On June 12, 2024, upon approval by the Board, the Company entered into the Fourth Amended and Restated Employment Agreement (the “Transition Agreement”) with the Company's former Chief Executive Officer (“CEO”), Tony J. Hunt, which amends and restates Mr. Hunt's Third Amended and Restated Employment Agreement with the Company dated as of May 26, 2022. Under the terms of the Transition Agreement, Mr. Hunt relinquished his position as the Company's CEO effective September 1, 2024 (the “Transition Date”) and transitioned to a new role as Executive Chair of the Board beginning on the Transition Date (the “CEO Transition”). It is anticipated that Mr. Hunt will continue to be involved in the business as the Executive Chair of the Board until March 2026 and will continue to be employed by the Company as an advisor thereafter, until March 2027. Under the terms of the Transition Agreement and the award agreements governing Mr. Hunt’s outstanding equity awards, Mr. Hunt’s unvested stock awards will continue to vest in accordance with their original terms. Furthermore, on June 28, 2024, the Company entered into an amendment (the “2024 Award Amendment”) to the equity awards granted to Mr. Hunt in 2024, which consisted of a stock option, restricted stock units (“RSUs”) and performance stock units (“PSUs” and together the “2024 Grants”). Pursuant to the terms of the 2024 Award Amendment, two-thirds of the 2024 Grants were forfeited, which equates to 32,776 shares of the Company’s common stock. Although Mr. Hunt’s unvested equity awards continue to vest in accordance with their original terms and there has been no amendment to Mr. Hunt’s outstanding equity awards other than the 2024 Award Amendment, the Company determined that under ASC 718, ”Compensation - Stock Compensation”, the CEO Transition represented a significant reduction in Mr. Hunt’s operating role with the Company for accounting purposes. This determination resulted in a Type III accounting modification of certain of Mr. Hunt’s unvested stock awards (improbable to probable) under ASC 718 (the “Equity Modification”) on June 12, 2024. As a result, for accounting purposes only, Mr. Hunt’s unvested awards were deemed cancelled and a new grant issued for his unvested shares with the value of these awards recalculated using a price of $ 136.00 per share, which was the opening stock price of the first day of trading following the public announcement of the CEO Transition. As a result of the Equity Modification, the Company recognized stock-based compensation expense for the modified awards of $ 22.4 million over the remaining requisite service period, which the Company determined to be between June 13, 2024 and September 1, 2024 and represented the remaining service period of Mr. Hunt’s role as CEO. The Company determined that the PSUs granted to Mr. Hunt in 2022 and 2023 should be accounted for as a Type IV accounting modification (improbable to improbable) in accordance with ASC 718, because vesting conditions before and after June 12, 2024 were improbable of being achieved. As a result of the Equity Modification and the forfeiture of the pro-rata portion of Mr. Hunt’s 2024 Grants, the Company recognized $ 17.4 million and $ 22.4 million of incremental stock-based compensation expense for the three and nine months ended September 30, 2024. Stock Issued for Earnout Payments In April 2024, the Company issued 28,638 shares of its common stock to former securityholders of Avitide to satisfy the contingent consideration obligation established under the Agreement and Plan of Merger and Reorganization (the “Avitide Agreement”) which the Company entered into as part of the acquisition of Avitide in September 2021. In March 2024, the Company issued 2,770 shares of its common stock to former securityholders of FlexBiosys to satisfy the contingent consideration obligation established under the FlexBiosys Agreement, which the Company entered into as part of the acquisition of FlexBiosys in April 2023. See Note 5, “ Acquisitions”, included in Part II, Item 8, “ Financial Statements and Supplementary Data,” to the Company’s Form 10-K/A for additional information on the acquisitions of Avitide and FlexBiosys and the contingent consideration. The shares issued to FlexBiosys represent 20 % of the earnout consideration earned in the First Earnout Year (as defined in the FlexBiosys Agreement) and the shares issued to Avitide represents 50 % of the earnout consideration earned in the Second Earnout Year (as defined in the Avitide Agreement). Stock-Based Compensation The following table presents stock-based compensation expense in the Company’s condensed consolidated statements of comprehensive income (loss): Three Months Ended Nine Months Ended 2024 2023 2024 2023 (Amounts in thousands) Cost of goods sold $ 396 $ 393 $ 1,498 $ 1,506 Research and development 887 700 2,335 2,095 Selling, general and administrative (1) 21,772 5,280 37,878 15,509 Total stock-based compensation $ 23,055 $ 6,373 $ 41,711 $ 19,110 (1) Selling, general and administrative stock-based compensation for the three and nine months ended September 30, 2024 includes $ 17.4 million and $ 22.4 million of expense related to the Equity Modification discussed above. Stock Options Information regarding option activity for the nine months ended September 30, 2024 under the Plans is summarized below: Shares Weighted Weighted- Aggregate Options outstanding at December 31, 2023 649,130 $ 85.97 Granted 77,014 $ 175.60 Exercised ( 43,725 ) $ 54.11 Forfeited/expired/cancelled (1) ( 32,027 ) $ 195.78 Options outstanding at September 30, 2024 650,392 $ 93.31 Options exercisable at September 30, 2024 398,851 $ 76.47 Vested and expected to vest at September 30, 2024 (2) 644,688 $ 92.66 5.31 $ 43,311 (1) Includes 13,057 options forfeited pursuant to the 2024 Award Amendment discussed above under “Chief Executive Officer Accounting Modifications” . (2) Represents the number of vested options as of September 30, 2024 plus the number of unvested options expected to vest as of September 30, 2024 based on the unvested outstanding options at September 30, 2024 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on September 30, 2024, the last business day of the third quarter of 2024, of $ 148.82 per share and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on September 30, 2024. The aggregate intrinsic value of stock options exercised during the nine months ended September 30, 2024 and 2023 was $ 4.7 million and $ 3.4 million, respectively. The weighted average grant date fair value of options granted during the nine months ended September 30, 2024 and 2023 was $ 89.09 and $ 85.70 , respectively. Stock Units The fair value of stock units is calculated using the closing price of the Company’s common stock on the date of grant. The Company recognizes expense on awards with service-based vesting over the employee’s requisite service period on a straight-line basis. The Company recognizes expense on performance-based awards over the vesting period based on the probability that the performance metrics will be achieved. Information regarding stock unit activity, which includes activity for restricted stock units and performance stock units, for the nine months ended September 30, 2024 under the Plans is summarized below: Shares Weighted Average Unvested at December 31, 2023 474,320 $ 155.59 Awarded 221,584 $ 180.02 Vested (1) ( 137,072 ) $ 144.80 Forfeited/cancelled (2) ( 82,452 ) $ 190.45 Unvested at September 30, 2024 476,380 $ 164.04 Vested and expected to vest at September 30, 2024 (3) 415,171 $ 162.37 (1) Includes 1,462 stock units that had vested but not settled as of September 30, 2024. (2) Includes 13,146 RSUs and 6,573 PSUs forfeited pursuant to the 2024 Award Amendment discussed above under ”Chief Executive Officer Accounting M odifications” . (3) Represents the number of vested stock units as of September 30, 2024 plus the number of unvested stock units expected to vest as of September 30, 2024 based on the unvested outstanding stock units at September 30, 2024 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value of stock units vested during the nine months ended September 30, 2024 and 2023 was $ 25.1 million and $ 32.3 million, respectively. The weighted average grant date fair value of stock units granted during the nine months ended September 30, 2024 and 2023 was $ 180.02 and $ 174.86 , respectively. As of September 30, 2024, there was $ 62.1 million of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 2.82 years. The Company expects 2,300,804 unvested options and stock units to vest over the next five years .

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Collaboration Agreements The Company licenses certain technologies that are, or may be, incorporated into its technology under several agreements and also has entered into several clinical research agreements that require the Company to fund certain research projects. Generally, the license agreements require the Company to pay annual maintenance fees and royalties on product sales once a product has been established using the technologies. Research and development expenses associated with license agreements were immaterial amounts for the three and nine months ended September 30, 2024 and 2023. In June 2018, the Company secured an agreement with Navigo Proteins GmbH (“Navigo”) for the exclusive co-development of multiple affinity ligands for which the Company holds commercialization rights. The Company is manufacturing and supplying the first of these ligands, NGL-Impact ® , exclusively to Purolite Life Sciences, an Ecolab Inc. company (“Purolite”), who is pairing the Company’s high-performance ligand with Purolite’s agarose jetting base bead technology used in their Jetted A50 Protein A resin product. The Company also signed a long-term supply agreement with Purolite for NGL-Impact and other potential additional affinity ligands that may advance from the Company’s Navigo collaboration. In September 2020, the Company and Navigo successfully completed co-development of an affinity ligand targeting the SARS-CoV-2 spike protein, that was used in the purification of vaccines for the COVID-19 pandemic, including emerging variants of the SARS-CoV-2 coronavirus. The Company has proceeded with scaling up and manufacturing this ligand and the development and validation of the related affinity chromatography resin, which is marketed by the Company. In September 2021, the Company and Navigo successfully completed co-development of a novel affinity ligand that addresses aggregation issues associated with pH sensitive antibodies and Fc-fusion proteins. The Company is manufacturing and supplying this ligand, NGL-Impact ® HipH, to Purolite. The Navigo and Purolite agreements are supportive of the Company’s strategy to secure and reinforce the Company’s proteins business. The Company made royalty payments to Navigo of $ 1.1 million and $ 0.8 million for the three months ended September 30, 2024 and 2023 , respectively, and payments of $ 2.9 million and $ 3.1 million for the nine months ended September 30, 2024 and 2023, respectively. Legal Proceedings From time to time, in the normal course of its operations, the Company is subject to litigation matters and claims relating to employee relations, business practices and patent infringement. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict, and the Company's view of these matters may change in the future as the litigation and events related thereto unfold. The Company expenses legal fees as incurred. The Company records a provision for contingent losses when it is both probably that a liability has been incurred and the amount of the loss can be reasonably estimated. An unfavorable outcome to any legal matter, if material, could have an adverse effect on the Company's operations or its financial results.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes (As Restated) For the three and nine months ended September 30, 2024, the Company recorded an income tax benefit of $ ( 0.5 ) million and an income tax expense of $ 3.2 million, respectively. The Company’s effective tax rate for the three and nine months ended September 30, 2024 was 43.0 % and 27.8 % , respectively, compared to ( 48.7 %) and 5.1 % for the corresponding periods in the prior year. In 2021, the Organization of Economic Co-operation and Development announced an Inclusive Framework on Base Erosion and Profit Sharing with the goal of achieving consensus around substantial changes to international tax policies, including the implementation of a minimum global effective tax rate of 15 %. The Company continues to evaluate the impacts of enacted legislation and pending legislation in the tax jurisdictions in which the Company operates. While various countries have implemented the legislature as of January 1, 2024, the Company does not expect a resulting material impact to its income tax provision for the 2024 fiscal year.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share, Basic [Abstract]
Earnings Per Share	13. Earnings Per Share A reconciliation of basic and diluted weighted average shares outstanding is as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (Amounts in thousands, except per share data) Numerator: (As Restated) (As Restated) Net (loss) income $ ( 654 ) $ 16,923 $ 8,355 $ 52,046 Denominator: Weighted average shares used in computing net (loss) income per share - basic 56,012 55,766 55,896 55,688 Effect of dilutive shares: Options and stock units — 439 419 469 Convertible senior notes (1) — 735 — 776 Dilutive potential common shares — 1,174 419 1,245 Denominator for diluted (loss) earnings per share - adjusted 56,012 56,940 56,315 56,933 (Loss) earnings per share: Basic $ ( 0.01 ) $ 0.30 $ 0.15 $ 0.93 Diluted $ ( 0.01 ) $ 0.30 $ 0.15 $ 0.91 (1) Represents the dilutive impact for the Company's 2019 Notes. As of September 30, 2024, the if-converted value is less than the outstanding principal of the 2023 Notes and are therefore anti-dilutive. Refer to Note 9, "Convertible Senior Notes," above for more information. As the Company was in a net loss position for the three months ended September 30, 2024, 358,372 shares of potentially dilutive options and stock units are considered anti-dilutive for the three months ended September 30, 2024. For the three and nine months ended September 30, 2024, 491,206 sh ares and 404,989 shares, respectively, of the Company’s common stock were excluded from the calculation of diluted (loss) earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares and were therefore anti-dilutive. Comparatively, for the three and nine months ended September 30, 2023 , 301,404 shares and 328,179 shares, respectively, were considered anti-dilutive. In July 2019, the Company issued $ 287.5 million aggregate principal amount of its 2019 Notes. As provided by the terms of the Second Supplemental Indenture underlying the 2019 Notes, upon conversion of the 2019 Notes, the Company will use a combination of cash and shares of the Company's common stock, settling the par value of the 2019 Notes in cash and any excess conversion premium in shares. On December 14, 2023, the Company exchanged, in a privately negotiated exchange, $ 309.9 million principal amount of 2023 Notes for $ 217.7 million principal amount of 2019 Notes and issued $ 290.1 million aggregate principal amount of 2023 Notes for $ 290.1 million in cash. Immediately following the closing of the Exchange Transaction mentioned above, $ 69.7 million in aggregate principal amount of the 2019 Notes remained outstanding as of December 31, 2023 with terms unchanged. During 2024, $ 0.2 million aggregate principal amount converted, bringing the remaining outstanding 2019 Notes to $ 69.5 million in aggregate principal amount. The remaining 2019 Notes matured and were paid off in full on July 15, 2024. As mentioned above and as provided by the terms of the Second Supplemental Indenture underlying the 2019 Notes, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company’s common stock. This means the Company settled the par value of the 2019 Notes in cash and any excess conversion premium in shares. The Company is required to reflect the dilutive effect of the convertible securities by application of the “if-converted” method, which means the denominator of the EPS calculation would include the total number of shares assuming the 2019 Notes had been fully converted at the beginning of the period. Accordingly, the par value of the 2019 Notes was not included in the calculation of diluted earnings per share, but the dilutive effect of the conversion premium was considered in the calculation of diluted earnings per share for any period the 2019 Notes were not matured, using the treasury stock method. The dilutive impact of the 2019 Notes was based on the difference between the Company’s current period average stock price and the conversion price of the 2019 Notes, provided there was a premium. Because the remaining 2019 Notes were redeemed at September 30, 2024 as mentioned above, there was no dilutive effect of the conversion premium included in the calculation of diluted earnings per share for the three and nine months ended September 30, 2024. For the three and nine months ended September 30, 2023 , the dilutive effect of the conversion premium included in the calculation of diluted earnings was 735,150 shares and 776,339 shares, respectively.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	14. Related Party Transactions Certain facilities leased by our subsidiary, Spectrum LifeSciences LLC (“Spectrum”) are owned by the Roy Eddleman Living Trust (the “Trust”). As of September 30, 2024 , the Trust owned greater than 5 % of the Company’s outstanding shares. Therefore, the Company considers the Trust to be a related party. The lease amounts paid to the Trust were negotiated in connection with the acquisition of Spectrum. The Company incurred rent expense totaling $ 0.1 million for each of the three months ended September 30, 2024 and 2023 related to these leases and incurred $ 0.5 million for each of the nine months ended September 30, 2024 and 2023 .

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Segment Reporting	15. Segment Reporting Operating segments are components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the CODM in deciding how to allocate resources and assess performance. Our CEO has been identified as the CODM. The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one operating segment and one reportable segment. Our CODM evaluates financial information on a consolidated basis. As a result, the required financial segment information can be found in the condensed consolidated financial statements of the Company disclosed herein. The following table represents the Company’s total revenue by customers’ geographic locations: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 (As Restated) Revenue by customers' geographic locations: North America 51 % 49 % 50 % 46 % Europe 33 % 34 % 35 % 34 % APAC/Other 16 % 17 % 15 % 20 % Total revenue 100 % 100 % 100 % 100 % Concentrations of Credit Risk and Significant Customers Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings, and credit exposure to any one issue, issuer (with the exception of U.S. Treasury obligations) and type of instrument is limited. At September 30, 2024 and December 31, 2023, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements. Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition. There was no revenue from customers that represented 10 % or more of the Company's total revenue for the three and nine months ended September 30, 2024 and 2023. No accounts receivable balance from a specific customer represented 10 % or more of the Company's total trade accounts receivable at September 30, 2024 and December 31, 2023.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated interim financial statements included herein have been prepared by Repligen Corporation in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP in annual financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023, which was filed with the SEC on November 18, 2024 (“Form 10-K/A”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The business and economic uncertainty resulting from global geopolitical conflicts, supply chain challenges and cost pressures on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K/A. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of its financial position as of September 30, 2024, its results of operations for the three and nine months ended September 30, 2024 and 2023 and cash flows for the nine months ended September 30, 2024 and 2023 . The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.
Assets Held for Sale	Assets Held for Sale An asset is considered to be held for sale when all the following criteria are met: (i) management commits to a plan to sell the asset; (ii) it is unlikely that the disposal plan will be significantly modified or discontinued; (iii) the asset is available for immediate sale in its present condition; (iv) actions required to complete the sale of the asset have been initiated; (v) sale of the asset is probable and the completed sale is expected to occur within one year; and (vi) the asset is actively being marketed for sale at a price that is reasonable given its current market value.
Convertible Instruments	Convertible Instruments The Company evaluates the embedded conversion feature within its convertible debt instruments under Accounting Standards Codification (“ASC”) 815, ”Derivatives and Hedging.” The Company refers to ASC 815-15 and ASC 815-40 to determine if the conversion feature meets the definition of a derivative and, if so, whether to bifurcate the conversion feature and account for it as a separate derivative liability. Based on the Company’s analysis, its Convertible Senior Notes do not have an embedded conversion feature requiring bifurcation under ASC 815-15 and thus are accounted for as a single unit of account, a liability under ASC 470, “ Debt.”
Recent Accounting Guidance	Recent Accounting Guidance The Company considers the applicability and impact of all Accounting Standards Updates (“ASU” or “ASUs”) and other recently issued guidance or rule decisions on their condensed consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial position or results of operations. Recently issued accounting guidance that the Company believes may be applicable to them is as follows: Recently Issued Accounting Guidance – Not Yet Adopted In March 2024, the SEC adopted final rules under SEC Release No. 33-11275 requiring public companies to provide certain climate-related information in their registration statements and annual reports. As part of the disclosures, registrants will be required to quantify certain effects of severe weather events and other natural conditions in a note to their audited financial statements. The rules were immediately challenged in a number of lawsuits, which were subsequently consolidated by the U.S. Court of Appeals for the Eighth Circuit. In April 2024, the SEC announced that it is staying implementation of the new rules pending resolution of the consolidated litigation before the Eighth Circuit. The Company is assessing the effect of compliance with the new rules on its condensed consolidated financial statements and related disclosures. In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “ Income Taxes (Topic 740) - Improvements to Income Tax Disclosures.” ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax disclosure included in its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application is permitted. Early adoption is also permitted. Besides a change in income tax disclosures, the Company does not expect the adoption of ASU 2023-09 to have a material impact on its condensed consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, “S egment Reporting (Topic 820) - Improvements to Reportable Segment Disclosures.” ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced annual and interim disclosures about significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”). The disclosures required under ASU 2023-07 are also required for public entities with a single reportable segment. ASU 2023-07 will be effective for the Company for annual periods beginning on January 1, 2024 and interim periods beginning on January 1, 2025. The amendments of this guidance apply retrospectively to all prior periods presented. Early adoption is permitted. Besides a change in presentation in the segment footnote, the Company does not expect the adoption of ASU 2023-07 to have a material impact on its condensed consolidated financial statements.

Restatement of Previously Iss_2

Restatement of Previously Issued Financial Statements (Tables)	9 Months Ended
	Sep. 30, 2024
Accounting Changes and Error Corrections [Abstract]
Schedule of Restatement of Previously Issued Financial Statements	December 31, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 751,323 $ — $ — $ 751,323 Marketable securities held to maturity — — — — Accounts receivable, net of reserves of $ 2,122 and $ 1,365 at 124,161 — — 124,161 Inventories, net 202,321 — — 202,321 Prepaid expenses and other current assets 33,238 303 — 33,541 Total current assets 1,111,043 303 — 1,111,346 Noncurrent assets: Property, plant and equipment, net 207,440 — — 207,440 Intangible assets, net 400,486 — 6,471 406,957 Goodwill 987,120 — — 987,120 Deferred tax assets 1,530 — — 1,530 Operating lease right of use assets 115,515 — — 115,515 Other noncurrent assets 1,277 — — 1,277 Total noncurrent assets 1,713,368 — 6,471 1,719,839 Total assets $ 2,824,411 $ 303 $ 6,471 $ 2,831,185 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 19,563 $ — $ — $ 19,563 Operating lease liability 5,631 — — 5,631 Current contingent consideration 12,983 — — 12,983 Accrued liabilities 50,533 6,780 — 57,313 Convertible Senior Notes due 2024, net 69,452 — — 69,452 Total current liabilities 158,162 6,780 — 164,942 Noncurrent liabilities: Convertible Senior Notes due 2028, net 510,143 — — 510,143 Deferred tax liabilities 40,466 ( 903 ) ( 239 ) 39,324 Noncurrent operating lease liability 126,578 — — 126,578 Noncurrent contingent consideration 14,070 — — 14,070 Other noncurrent liabilities 3,789 — 7,494 11,283 Total noncurrent liabilities 695,046 ( 903 ) 7,255 701,398 Total liabilities 853,208 5,877 7,255 866,340 Commitments and contingencies (Note 14) Stockholders' equity: Preferred stock, $ 0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding — — — — Common stock, $ 0.01 par value; 80,000,000 shares authorized; 55,766,078 shares at December 31, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding 558 — — 558 Additional paid-in capital 1,569,227 — — 1,569,227 Accumulated other comprehensive loss ( 37,431 ) ( 377 ) — ( 37,808 ) Accumulated earnings 438,849 ( 5,197 ) ( 784 ) 432,868 Total stockholders’ equity 1,971,203 ( 5,574 ) ( 784 ) 1,964,845 Total liabilities and stockholders’ equity $ 2,824,411 $ 303 $ 6,471 $ 2,831,185 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated Revenue: Products $ 141,156 $ — $ — $ 141,156 $ 482,910 $ ( 17,280 ) $ — $ 465,630 Royalty and other revenue 36 — — 36 111 — — 111 Total revenue 141,192 — — 141,192 483,021 ( 17,280 ) — 465,741 Costs and operating expenses: Cost of product revenue 104,634 — — 104,634 265,786 — — 265,786 Research and development 10,577 — — 10,577 32,437 — — 32,437 Selling, general and administrative 55,465 — 117 55,582 160,601 — 353 160,954 Contingent consideration ( 34,292 ) — — ( 34,292 ) ( 31,266 ) — — ( 31,266 ) Total costs and operating expenses 136,384 — 117 136,501 427,558 — 353 427,911 Income from operations 4,808 — ( 117 ) 4,691 55,463 ( 17,280 ) ( 353 ) 37,830 Other income (expenses): Investment income 6,662 — — 6,662 18,112 — — 18,112 Interest expense ( 269 ) — ( 139 ) ( 408 ) ( 813 ) — ( 414 ) ( 1,227 ) Amortization of debt issuance costs ( 459 ) — — ( 459 ) ( 1,373 ) — — ( 1,373 ) Other income (expenses) 895 — — 895 1,500 — — 1,500 Other income (expenses), net 6,829 — ( 139 ) 6,690 17,426 — ( 414 ) 17,012 Income before income taxes 11,637 — ( 256 ) 11,381 72,889 ( 17,280 ) ( 767 ) 54,842 Income tax (benefit) provision ( 6,535 ) 1,053 ( 60 ) ( 5,542 ) 5,824 ( 2,849 ) ( 179 ) 2,796 Net income $ 18,172 $ ( 1,053 ) $ ( 196 ) $ 16,923 $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Earnings per share: Basic $ 0.33 $ ( 0.02 ) $ ( 0.01 ) $ 0.30 $ 1.20 $ ( 0.26 ) $ ( 0.01 ) $ 0.93 Diluted (Note 13) $ 0.32 $ ( 0.02 ) $ — $ 0.30 $ 1.18 $ ( 0.25 ) $ ( 0.02 ) $ 0.91 Weighted average common shares outstanding: Basic 55,766 — — 55,766 55,688 — — 55,688 Diluted (Note 13) 56,940 — — 56,940 56,933 — — 56,933 Net income $ 18,172 $ ( 1,053 ) $ ( 196 ) $ 16,923 $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Other comprehensive income (loss): Foreign currency translation adjustment ( 6,382 ) 502 — ( 5,880 ) ( 9,177 ) 205 — ( 8,972 ) Comprehensive income $ 11,790 $ ( 551 ) $ ( 196 ) $ 11,043 $ 57,888 $ ( 14,226 ) $ ( 588 ) $ 43,074 Accumulated Other Comprehensive Loss Accumulated Earnings Total Stockholders' Equity As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated $ $ $ $ $ $ $ $ $ $ $ $ Balance at June 30, 2023 ( 37,189 ) ( 297 ) — ( 37,486 ) 446,165 ( 13,378 ) ( 392 ) 432,395 1,970,926 ( 13,675 ) ( 392 ) 1,956,859 Net income — — — — 18,172 ( 1,053 ) ( 196 ) 16,923 18,172 ( 1,053 ) ( 196 ) 16,923 Translation adjustment ( 6,382 ) 502 — ( 5,880 ) — — — — ( 6,382 ) 502 — ( 5,880 ) Balance at September 30, 2023 ( 43,571 ) 205 — ( 43,366 ) 464,337 ( 14,431 ) ( 588 ) 449,318 1,988,557 ( 14,226 ) ( 588 ) 1,973,743 Accumulated Other Comprehensive Loss Accumulated Earnings Total Stockholders' Equity As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated As Previously Reported Revenue Adjustments Other Adjustments As Restated $ $ $ $ $ $ $ $ $ $ $ $ Balance at December 31, 2022 ( 34,394 ) — — ( 34,394 ) 397,272 — — 397,272 1,910,700 — — 1,910,700 Net income — — — — 67,065 ( 14,431 ) ( 588 ) 52,046 67,065 ( 14,431 ) ( 588 ) 52,046 Translation adjustment ( 9,177 ) 205 — ( 8,972 ) — — — — ( 9,177 ) 205 — ( 8,972 ) Balance at September 30, 2023 ( 43,571 ) 205 — ( 43,366 ) 464,337 ( 14,431 ) ( 588 ) 449,318 1,988,557 ( 14,226 ) ( 588 ) 1,973,743 Nine Months Ended September 30, 2023 As Previously Reported Revenue Adjustments Other Adjustments As Restated Cash flows from operating activities: Net income $ 67,065 $ ( 14,431 ) $ ( 588 ) $ 52,046 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 50,942 — 353 51,295 Amortization of debt issuance costs 1,373 — — 1,373 Stock-based compensation 19,110 — — 19,110 Deferred income taxes, net ( 9,756 ) 667 ( 179 ) ( 9,268 ) Contingent consideration ( 31,266 ) — — ( 31,266 ) Non-cash interest income ( 2,023 ) — — ( 2,023 ) Operating lease right of use asset amortization 10,203 — — 10,203 Other 861 — 414 1,275 Changes in operating assets and liabilities, excluding impact of acquisitions: Accounts receivable 8,315 — — 8,315 Inventories 25,979 — — 25,979 Prepaid expenses and other assets ( 10,733 ) ( 2,016 ) — ( 12,749 ) Other assets ( 707 ) — — ( 707 ) Accounts payable ( 8,619 ) — — ( 8,619 ) Accrued expenses ( 28,294 ) 15,780 — ( 12,514 ) Operating lease liabilities ( 7,676 ) — — ( 7,676 ) Long-term liabilities 79 — — 79 Total cash provided by operating activities 84,853 — — 84,853 Cash flows from investing activities: Acquisitions, net of cash acquired ( 27,843 ) — — ( 27,843 ) Proceeds from maturity of marketable securities held to maturity 102,323 — — 102,323 Additions to capitalized software costs ( 2,736 ) — — ( 2,736 ) Purchases of property, plant and equipment ( 25,135 ) — — ( 25,135 ) Purchase of intellectual property — — — — Other investing activities 21 — — 21 Total cash provided by (used in) investing activities 46,630 — — 46,630 Cash flows from financing activities: Proceeds from exercise of stock options 356 — — 356 Payment of tax withholding obligation on vesting of restricted stock ( 12,178 ) — — ( 12,178 ) Repayment of Convertible Senior Notes ( 33 ) — — ( 33 ) Payment of earnout consideration ( 7,298 ) — — ( 7,298 ) Proceeds from issuance of common stock, net ( 13 ) — — ( 13 ) Total cash used in financing activities ( 19,166 ) — — ( 19,166 ) Effect of exchange rate changes on cash and cash equivalents ( 4,996 ) — — ( 4,996 ) Net increase (decrease) in cash and cash equivalents 107,321 — — 107,321 Cash, cash equivalents and restricted cash, beginning of period 523,458 — — 523,458 Cash and cash equivalents, end of period $ 630,779 $ — $ — $ 630,779 Supplemental disclosure of non-cash investing and financing activities: Assets acquired under operating leases $ 1,129 $ — $ — $ 1,129 Fair value of 31,415 shares of common stock issued for the acquisition of $ 5,465 $ — $ — $ 5,465 Fair value of 42,621 shares of common stock issued for the Avitide, Inc. $ 7,229 $ — $ — $ 7,229

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 30, 2024 and December 31, 2023 (amounts in thousands): As of September 30, 2024 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 669,347 $ — $ — $ 669,347 Liabilities: Current contingent consideration $ — $ — $ 13,936 $ 13,936 As of December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 658,574 $ — $ — $ 658,574 Liabilities: Current contingent consideration $ — $ — $ 12,983 $ 12,983 Noncurrent contingent consideration $ — $ — $ 14,070 $ 14,070
Schedule of Reconciliation of the Change in the Fair Value of Contingent Consideration - Earnout	A reconciliation of the change in the fair value of contingent consideration – earnouts is included in the following table (amounts in thousands): Balance at December 31, 2023 $ 27,053 Payment of contingent consideration earnouts ( 13,117 ) Decrease in fair value of contingent consideration earnouts — Balance at September 30, 2024 $ 13,936
Schedule of Contingent Consideration Earnout Expect to be Required to Settle Include Significant Unobservable Inputs	The recurring Level 3 fair value measurement of our contingent consideration obligations for Avitide, FlexBiosys and Metenova include the following significant unobservable inputs (amounts in thousands, except percent data): Contingent Consideration Earnout Fair Value as of Valuation Technique Unobservable Input Range Weighted Average (1) Probability of Success 100 % 100 % Commercialization-based payments $ 9,678 Monte Carlo Earnout Discount Rate 5.8 %- 5.9 % 5.9 % Volatility 12.5 %- 24.6 % 13.9 % Revenue and Volume- $ 361 Monte Carlo Revenue & Volume 2.5 %- 9.3 % 5.1 % Earnout Discount Rate 5.8 %- 7.2 % 5.8 % Probability of 100 % 100 % Manufacturing line expansions $ 3,897 Probability-weighted present value Earnout Discount Rate 6.1 %- 6.4 % 6.3 % (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2024
Metenova Holding AB
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The components and final allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 5,768 Accounts receivable 3,730 Inventory 4,477 Prepaid expenses and other current assets 470 Property and equipment 433 Operating lease right of use asset 615 Customer relationships 12,659 Developed technology 44,377 Trademark and tradename 939 Non-competition agreements 787 Goodwill 115,722 Accounts payable ( 1,432 ) Accrued liabilities ( 2,934 ) Operating lease liability ( 275 ) Noncurrent deferred tax liability ( 12,481 ) Noncurrent operating lease liability ( 255 ) Fair value of net assets acquired $ 172,600
Schedule of Identified Intangible Assets and Estimated Useful Lives	The following table sets forth the components of the identified intangible assets associated with the Metenova Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 15 years $ 12,659 Developed technology 15 years 44,377 Trademark and tradename 15 years 939 Non-competition agreements 2 years 787 $ 58,762
FlexBiosys
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The components and final allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 1,090 Accounts receivable 683 Inventory 667 Prepaid expenses and other current assets 35 Property and equipment 12,034 Operating lease right of use asset 3,537 Customer relationships 2,530 Developed technology 9,860 Trademark and tradename 30 Non-competition agreements 220 Goodwill 14,321 Other noncurrent assets 10 Accounts payable ( 136 ) Accrued liabilities ( 314 ) Operating lease liability ( 39 ) Noncurrent operating lease liability ( 3,498 ) Fair value of net assets acquired $ 41,030
Schedule of Identified Intangible Assets and Estimated Useful Lives	The following table sets forth the components of the identified intangible assets associated with the FlexBiosys Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 12 years $ 2,530 Developed technology 16 years 9,860 Trademark and tradename 4 years 30 Non-competition agreements 5 years 220 $ 12,640

Restructuring Plan (Tables)

Restructuring Plan (Tables)	9 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Summary of Restructuring Activities by Type of Cost	The following tables summarize the charges related to restructuring activities by type of cost for the periods presented on the Company’s condensed consolidated statements of comprehensive income (loss): Three Months Ended September 30, 2024 Severance and Employee-Related Costs Facility and Other Exit Costs Total (Amounts in thousands) Cost of goods sold $ 23 $ 1,461 $ 1,484 Selling, general and administrative 631 1,037 1,668 Other (income) expenses — ( 234 ) ( 234 ) $ 654 $ 2,264 $ 2,918 Nine Months Ended September 30, 2024 Severance and Employee-Related Costs Accelerated Depreciation Facility and Other Exit Costs Total (Amounts in thousands) Cost of goods sold $ 876 $ 19 $ 1,661 $ 2,556 Research and development 449 — — 449 Selling, general and administrative 1,486 — 1,054 2,540 Other (income) expenses — — ( 234 ) ( 234 ) $ 2,811 $ 19 $ 2,481 $ 5,311 Three and Nine Months Ended September 30, 2023 Severance and Employee-Related Costs Inventory Write-Off Accelerated Depreciation Facility and Other Exit Costs Total (Amounts in thousands) Cost of goods sold $ 1,654 $ 17,185 $ 3,788 $ 84 $ 22,711 Research and development 34 — 1 — 35 Selling, general and administrative 1,142 — 27 97 1,266 $ 2,830 $ 17,185 $ 3,816 $ 181 $ 24,012
Summary of Activity Related to Restructuring Plan	Activity related to the Restructuring Plan for the nine months ended September 30, 2024 was as follows (amounts in thousands): Restructuring Liability Restructuring Costs Amounts Paid in 2024 Noncash Restructuring Items Restructuring Liability Severance & employee-related costs $ 464 $ 2,811 $ ( 3,030 ) $ ( 49 ) $ 196 Accelerated depreciation — 19 — ( 19 ) — Facility and other exit costs — 2,481 ( 2,715 ) 234 — Total $ 464 $ 5,311 $ ( 5,745 ) $ 166 $ 196

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Disaggregation of Revenue	Revenues for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (Amounts in thousands) (As Restated) Product revenue $ 154,834 $ 141,156 $ 466,784 $ 465,630 Royalty and other income 37 36 108 111 Total revenue $ 154,871 $ 141,192 $ 466,892 $ 465,741
Summary of Receivables and Deferred Revenue from Contracts with Customers	The following table provides information about receivables and deferred revenue from contracts with customers as of September 30, 2024 and December 31, 2023 (amounts in thousands): September 30, December 31, 2024 2023 (As Restated) Balances from contracts with customers only: Accounts receivable $ 129,026 $ 124,161 Deferred revenue (included in accrued liabilities and $ 16,884 $ 17,536 Revenue recognized during periods presented relating to: The beginning deferred revenue balance $ 15,365 $ 18,751

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill And Other Intangible Assets Disclosure [Abstract]
Changes in Carrying Value of Goodwill	The following table represents the change in the carrying value of goodwill for the nine months ended September 30, 2024 (amounts in thousands): Balance at December 31, 2023 $ 987,120 Measurement period adjustment - Metenova ( 56 ) Cumulative translation adjustment 556 Balance at September 30, 2024 $ 987,620
Schedule of Intangible Assets	Intangible assets, net, consisted of the following at September 30, 2024: September 30, 2024 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology – developed $ 256,482 $ ( 56,803 ) $ 199,679 16 Patents 240 ( 240 ) — 8 Customer relationships 270,049 ( 97,210 ) 172,839 15 Trademarks 8,757 ( 2,183 ) 6,574 19 Other intangibles 3,917 ( 2,955 ) 962 3 Total finite-lived intangible assets 539,445 ( 159,391 ) 380,054 15 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 540,145 $ ( 159,391 ) $ 380,754 Intangible assets, net, consisted of the following at December 31, 2023: December 31, 2023 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: (As Restated) (As Restated) (As Restated) Technology – developed $ 256,536 $ ( 44,633 ) $ 211,903 16 Patents 240 ( 240 ) — 8 Customer relationships 269,949 ( 83,963 ) 185,986 15 Trademarks 8,757 ( 1,789 ) 6,968 19 Other intangibles 3,914 ( 2,514 ) 1,400 3 Total finite-lived intangible assets 539,396 ( 133,139 ) 406,257 15 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 540,096 $ ( 133,139 ) $ 406,957
Schedule of Amortization Expense for Amortized Intangible Assets	As of September 30, 2024, the Company expects to record the following amortization expense in future periods (amounts in thousands): Estimated Amortization For the Years Ended December 31, Expense 2024 (remaining three months) $ 8,620 2025 34,354 2026 34,000 2027 33,965 2028 33,863 2029 and thereafter 235,252 Total $ 380,054

Consolidated Balance Sheet De_2

Consolidated Balance Sheet Detail (Tables)	9 Months Ended
	Sep. 30, 2024
Disclosure Text Block [Abstract]
Inventories	Inventories, net consists of the following: September 30, December 31, 2024 2023 (Amounts in thousands) Raw materials $ 106,843 $ 123,598 Work-in-process 6,794 4,492 Finished products 68,828 74,231 Total inventories, net $ 182,465 $ 202,321
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment, net consist of the following: September 30, December 31, 2024 2023 (Amounts in thousands) Land $ 893 $ 992 Buildings 725 1,667 Leasehold improvements 142,506 126,663 Equipment 120,029 114,606 Furniture, fixtures and office equipment 10,035 9,077 Computer hardware and software 40,790 35,528 Construction in progress 40,241 47,086 Other 488 544 Total property, plant and equipment 355,707 336,163 Less - Accumulated depreciation ( 153,124 ) ( 128,723 ) Total property, plant and equipment, net $ 202,583 $ 207,440
Accrued liabilities	Accrued liabilities Accrued liabilities consist of the following: September 30, December 31, 2024 2023 (Amounts in thousands) (As Restated) Employee compensation $ 28,104 $ 16,660 Deferred revenue 16,446 17,067 Income taxes payable 148 6,814 Other 16,204 16,772 Total accrued liabilities $ 60,902 $ 57,313

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Instrument [Line Items]
Carrying Value of Convertible Senior Notes	The carrying value of the Company's Convertible Senior Notes is as follows: September 30, December 31, (Amounts in thousands) 1.00% Convertible Senior Notes due 2028: Principal amount $ 600,000 $ 600,000 Unamortized debt discount ( 71,261 ) ( 81,457 ) Unamortized debt issuance costs ( 7,132 ) ( 8,400 ) Carrying amount - Convertible Senior Notes due 2028, net $ 521,607 $ 510,143 0.375% Convertible Senior Notes due 2024: Principal amount $ — $ 69,700 Unamortized debt issuance costs — ( 248 ) Carrying amount - Convertible Senior Notes due 2024, net $ — $ 69,452
2023 Notes
Debt Instrument [Line Items]
Schedule of convertible note interest expense	The following table sets forth total interest expense recognized related to the 2023 Notes for the three and nine months ended September 30, 2024 for which there were no comparable amounts for the same periods of 2023: Three Months Ended Nine Months Ended 2024 2024 (Amounts in thousands, except percentage data) Contractual interest expense – 2023 Notes $ 1,500 $ 4,500 Amortization of debt discount – 2023 Notes 3,473 10,197 Amortization of debt issuance costs – 2023 Notes 410 1,190 Total $ 5,383 $ 15,887 Effective interest rate of the liability component 4.39 % 4.39 %
2019 Notes
Debt Instrument [Line Items]
Schedule of convertible note interest expense	The following table sets forth total interest expense recognized related to the 2019 Notes: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (Amounts in thousands, except percentage data) Contractual interest expense – 2019 Notes $ 11 $ 269 $ 141 $ 808 Amortization of debt issuance costs – 2019 Notes 19 459 243 1,373 Total $ 30 $ 728 $ 384 $ 2,181 Effective interest rate of the liability component 1.00 % 1.00 % 1.00 % 1.00 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stock-Based Compensation Expense	The following table presents stock-based compensation expense in the Company’s condensed consolidated statements of comprehensive income (loss): Three Months Ended Nine Months Ended 2024 2023 2024 2023 (Amounts in thousands) Cost of goods sold $ 396 $ 393 $ 1,498 $ 1,506 Research and development 887 700 2,335 2,095 Selling, general and administrative (1) 21,772 5,280 37,878 15,509 Total stock-based compensation $ 23,055 $ 6,373 $ 41,711 $ 19,110 (1) Selling, general and administrative stock-based compensation for the three and nine months ended September 30, 2024 includes $ 17.4 million and $ 22.4 million of expense related to the Equity Modification discussed above.
Summary of Option Activity	Information regarding option activity for the nine months ended September 30, 2024 under the Plans is summarized below: Shares Weighted Weighted- Aggregate Options outstanding at December 31, 2023 649,130 $ 85.97 Granted 77,014 $ 175.60 Exercised ( 43,725 ) $ 54.11 Forfeited/expired/cancelled (1) ( 32,027 ) $ 195.78 Options outstanding at September 30, 2024 650,392 $ 93.31 Options exercisable at September 30, 2024 398,851 $ 76.47 Vested and expected to vest at September 30, 2024 (2) 644,688 $ 92.66 5.31 $ 43,311 (1) Includes 13,057 options forfeited pursuant to the 2024 Award Amendment discussed above under “Chief Executive Officer Accounting Modifications” . (2) Represents the number of vested options as of September 30, 2024 plus the number of unvested options expected to vest as of September 30, 2024 based on the unvested outstanding options at September 30, 2024 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.
Summary of Restricted Stock Unit Activity	Information regarding stock unit activity, which includes activity for restricted stock units and performance stock units, for the nine months ended September 30, 2024 under the Plans is summarized below: Shares Weighted Average Unvested at December 31, 2023 474,320 $ 155.59 Awarded 221,584 $ 180.02 Vested (1) ( 137,072 ) $ 144.80 Forfeited/cancelled (2) ( 82,452 ) $ 190.45 Unvested at September 30, 2024 476,380 $ 164.04 Vested and expected to vest at September 30, 2024 (3) 415,171 $ 162.37 (1) Includes 1,462 stock units that had vested but not settled as of September 30, 2024. (2) Includes 13,146 RSUs and 6,573 PSUs forfeited pursuant to the 2024 Award Amendment discussed above under ”Chief Executive Officer Accounting M odifications” . (3) Represents the number of vested stock units as of September 30, 2024 plus the number of unvested stock units expected to vest as of September 30, 2024 based on the unvested outstanding stock units at September 30, 2024 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share, Basic [Abstract]
Basic and Diluted Weighted Average Shares Outstanding	A reconciliation of basic and diluted weighted average shares outstanding is as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 (Amounts in thousands, except per share data) Numerator: (As Restated) (As Restated) Net (loss) income $ ( 654 ) $ 16,923 $ 8,355 $ 52,046 Denominator: Weighted average shares used in computing net (loss) income per share - basic 56,012 55,766 55,896 55,688 Effect of dilutive shares: Options and stock units — 439 419 469 Convertible senior notes (1) — 735 — 776 Dilutive potential common shares — 1,174 419 1,245 Denominator for diluted (loss) earnings per share - adjusted 56,012 56,940 56,315 56,933 (Loss) earnings per share: Basic $ ( 0.01 ) $ 0.30 $ 0.15 $ 0.93 Diluted $ ( 0.01 ) $ 0.30 $ 0.15 $ 0.91 (1) Represents the dilutive impact for the Company's 2019 Notes. As of September 30, 2024, the if-converted value is less than the outstanding principal of the 2023 Notes and are therefore anti-dilutive. Refer to Note 9, "Convertible Senior Notes," above for more information.

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2024
Text Block [Abstract]
Percentage by Geographic Area or Significant Customers	The following table represents the Company’s total revenue by customers’ geographic locations: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 (As Restated) Revenue by customers' geographic locations: North America 51 % 49 % 50 % 46 % Europe 33 % 34 % 35 % 34 % APAC/Other 16 % 17 % 15 % 20 % Total revenue 100 % 100 % 100 % 100 %

Restatement of Previously Iss_3

Restatement of Previously Issued Financial Statements - Additional information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cancelled purchase orders in exchange for payment	$ 17.3
Product
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Payment to purchase component of product revenue	$ 17.3

Restatement of Previously Iss_4

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 783,964		$ 751,323
Marketable securities held to maturity			0
Accounts receivable, net of reserves of $2,122 and $1,365 at December 31, 2023 and December 31, 2022, respectively	129,026		124,161
Inventories, net	182,465		202,321
Prepaid expenses and other current assets	36,115		33,541
Total current assets	1,131,570		1,111,346
Property, plant and equipment, net	202,583		207,440
Intangible assets, net	380,754		406,957
Goodwill	987,620		987,120
Deferred tax assets	101		1,530
Operating lease right of use assets	127,268		115,515
Other noncurrent assets	748		1,277
Total noncurrent assets	1,699,074		1,719,839
Total assets	2,830,644		2,831,185
Current liabilities:
Accounts payable	21,357		19,563
Operating lease liability	12,171		5,631
Current contingent consideration	13,936		12,983
Accrued liabilities	60,902		57,313
Convertible Senior Notes due 2024, net	0		69,452
Total current liabilities	108,366		164,942
Convertible Senior Notes due 2028, net	521,607		510,143
Deferred tax liabilities	33,686		39,324
Noncurrent operating lease liability	138,693		126,578
Noncurrent contingent consideration	0		14,070
Other noncurrent liabilities	11,606		11,283
Total noncurrent liabilities	705,592		701,398
Total liabilities	813,958		866,340
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	0		0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,766,078 shares at December 31, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding	560		558
Additional paid-in capital	1,609,526		1,569,227
Accumulated other comprehensive loss	(34,623)		(37,808)
Accumulated earnings	441,223		432,868
Total stockholders' equity	2,016,686	$ 1,984,438	1,964,845	$ 1,973,743	$ 1,956,859	$ 1,910,700
Total liabilities and stockholders' equity	$ 2,830,644		2,831,185
Previously Reported
Current assets:
Cash and cash equivalents			751,323
Marketable securities held to maturity			0
Accounts receivable, net of reserves of $2,122 and $1,365 at December 31, 2023 and December 31, 2022, respectively			124,161
Inventories, net			202,321
Prepaid expenses and other current assets			33,238
Total current assets			1,111,043
Property, plant and equipment, net			207,440
Intangible assets, net			400,486
Goodwill			987,120
Deferred tax assets			1,530
Operating lease right of use assets			115,515
Other noncurrent assets			1,277
Total noncurrent assets			1,713,368
Total assets			2,824,411
Current liabilities:
Accounts payable			19,563
Operating lease liability			5,631
Current contingent consideration			12,983
Accrued liabilities			50,533
Convertible Senior Notes due 2024, net			69,452
Total current liabilities			158,162
Convertible Senior Notes due 2028, net			510,143
Deferred tax liabilities			40,466
Noncurrent operating lease liability			126,578
Noncurrent contingent consideration			14,070
Other noncurrent liabilities			3,789
Total noncurrent liabilities			695,046
Total liabilities			853,208
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding			0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,766,078 shares at December 31, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding			558
Additional paid-in capital			1,569,227
Accumulated other comprehensive loss			(37,431)
Accumulated earnings			438,849
Total stockholders' equity			1,971,203	1,988,557	1,970,926	$ 1,910,700
Total liabilities and stockholders' equity			2,824,411
Revenue Adjustments
Current assets:
Cash and cash equivalents			0
Marketable securities held to maturity			0
Accounts receivable, net of reserves of $2,122 and $1,365 at December 31, 2023 and December 31, 2022, respectively			0
Inventories, net			0
Prepaid expenses and other current assets			303
Total current assets			303
Property, plant and equipment, net			0
Intangible assets, net			0
Goodwill			0
Deferred tax assets			0
Operating lease right of use assets			0
Other noncurrent assets			0
Total noncurrent assets			0
Total assets			303
Current liabilities:
Accounts payable			0
Operating lease liability			0
Current contingent consideration			0
Accrued liabilities			6,780
Convertible Senior Notes due 2024, net			0
Total current liabilities			6,780
Convertible Senior Notes due 2028, net			0
Deferred tax liabilities			(903)
Noncurrent operating lease liability			0
Noncurrent contingent consideration			0
Other noncurrent liabilities			0
Total noncurrent liabilities			(903)
Total liabilities			5,877
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding			0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,766,078 shares at December 31, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding			0
Additional paid-in capital			0
Accumulated other comprehensive loss			(377)
Accumulated earnings			(5,197)
Total stockholders' equity			(5,574)	(14,226)	(13,675)
Total liabilities and stockholders' equity			303
Other Adjustments
Current assets:
Cash and cash equivalents			0
Marketable securities held to maturity			0
Accounts receivable, net of reserves of $2,122 and $1,365 at December 31, 2023 and December 31, 2022, respectively			0
Inventories, net			0
Prepaid expenses and other current assets			0
Total current assets			0
Property, plant and equipment, net			0
Intangible assets, net			6,471
Goodwill			0
Deferred tax assets			0
Operating lease right of use assets			0
Other noncurrent assets			0
Total noncurrent assets			6,471
Total assets			6,471
Current liabilities:
Accounts payable			0
Operating lease liability			0
Current contingent consideration			0
Accrued liabilities			0
Convertible Senior Notes due 2024, net			0
Total current liabilities			0
Convertible Senior Notes due 2028, net			0
Deferred tax liabilities			(239)
Noncurrent operating lease liability			0
Noncurrent contingent consideration			0
Other noncurrent liabilities			7,494
Total noncurrent liabilities			7,255
Total liabilities			7,255
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding			0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,766,078 shares at December 31, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding			0
Additional paid-in capital			0
Accumulated other comprehensive loss			0
Accumulated earnings			(784)
Total stockholders' equity			(784)	$ (588)	$ (392)
Total liabilities and stockholders' equity			$ 6,471

Restatement of Previously Iss_5

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Balance Sheets (Parenthetical) (Detail) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounting Changes and Error Corrections [Abstract]
Accounts receivable, reserve for doubtful accounts	$ 1,961	$ 2,122	$ 1,365
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000	80,000,000
Common stock, shares issued	56,026,725	55,766,078	55,557,698
Common stock, shares outstanding	56,026,725	55,766,078	55,557,698

Restatement of Previously Iss_6

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Statements Of Comprehensive Income (Loss) (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Revenue	$ 154,871	$ 141,192	$ 466,892	$ 465,741
Costs and operating expenses:
Cost of product revenue	77,383	104,634	231,088	265,786
Research and development	9,710	10,577	31,523	32,437
Selling, general and administrative	75,610	55,582	202,894	160,954
Contingent consideration	0	(34,292)	0	(31,266)
Total costs and operating expenses	162,703	136,501	465,505	427,911
Income from operations	(7,832)	4,691	1,387	37,830
Other income (expenses):
Investment income	9,130	6,662	27,534	18,112
Interest expense	(5,122)	(408)	(15,269)	(1,227)
Amortization of debt issuance costs	(429)	(459)	(1,432)	(1,373)
Other income (expenses)	3,104	895	(647)	1,500
Other income (expenses), net	6,683	6,690	10,186	17,012
Income before income taxes	(1,149)	11,381	11,573	54,842
Income tax (benefit) provision	(495)	(5,542)	3,218	2,796
Net income	$ (654)	$ 16,923	$ 8,355	$ 52,046
Earnings per share:
Basic	$ (0.01)	$ 0.3	$ 0.15	$ 0.93
Diluted (Note 13)	$ (0.01)	$ 0.3	$ 0.15	$ 0.91
Weighted average common shares outstanding:
Basic	56,012	55,766	55,896	55,688
Diluted (Note 13)	56,012	56,940	56,315	56,933
Net income	$ (654)	$ 16,923	$ 8,355	$ 52,046
Other comprehensive income (loss):
Foreign currency translation adjustment	9,822	(5,880)	3,185	(8,972)
Comprehensive income	9,168	11,043	11,540	43,074
Product
Revenue:
Revenue	154,834	141,156	466,784	465,630
Royalty and other revenue
Revenue:
Revenue	$ 37	36	$ 108	111
Previously Reported
Revenue:
Revenue		141,192		483,021
Costs and operating expenses:
Cost of product revenue		104,634		265,786
Research and development		10,577		32,437
Selling, general and administrative		55,465		160,601
Contingent consideration		(34,292)		(31,266)
Total costs and operating expenses		136,384		427,558
Income from operations		4,808		55,463
Other income (expenses):
Investment income		6,662		18,112
Interest expense		(269)		(813)
Amortization of debt issuance costs		(459)		(1,373)
Other income (expenses)		895		1,500
Other income (expenses), net		6,829		17,426
Income before income taxes		11,637		72,889
Income tax (benefit) provision		(6,535)		5,824
Net income		$ 18,172		$ 67,065
Earnings per share:
Basic		$ 0.33		$ 1.2
Diluted (Note 13)		$ 0.32		$ 1.18
Weighted average common shares outstanding:
Basic		55,766		55,688
Diluted (Note 13)		56,940		56,933
Net income		$ 18,172		$ 67,065
Other comprehensive income (loss):
Foreign currency translation adjustment		(6,382)		(9,177)
Comprehensive income		11,790		57,888
Previously Reported | Product
Revenue:
Revenue		141,156		482,910
Previously Reported | Royalty and other revenue
Revenue:
Revenue		36		111
Revenue Adjustments
Revenue:
Revenue		0		(17,280)
Costs and operating expenses:
Cost of product revenue		0		0
Research and development		0		0
Selling, general and administrative		0		0
Contingent consideration		0		0
Total costs and operating expenses		0		0
Income from operations		0		(17,280)
Other income (expenses):
Investment income		0		0
Interest expense		0		0
Amortization of debt issuance costs		0		0
Other income (expenses)		0		0
Other income (expenses), net		0		0
Income before income taxes		0		(17,280)
Income tax (benefit) provision		1,053		(2,849)
Net income		$ (1,053)		$ (14,431)
Earnings per share:
Basic		$ (0.02)		$ (0.26)
Diluted (Note 13)		$ (0.02)		$ (0.25)
Weighted average common shares outstanding:
Basic		0		0
Diluted (Note 13)		0		0
Net income		$ (1,053)		$ (14,431)
Other comprehensive income (loss):
Foreign currency translation adjustment		502		205
Comprehensive income		(551)		(14,226)
Revenue Adjustments | Product
Revenue:
Revenue		0		(17,280)
Revenue Adjustments | Royalty and other revenue
Revenue:
Revenue		0		0
Other Adjustments
Revenue:
Revenue		0		0
Costs and operating expenses:
Cost of product revenue		0		0
Research and development		0		0
Selling, general and administrative		117		353
Contingent consideration		0		0
Total costs and operating expenses		117		353
Income from operations		(117)		(353)
Other income (expenses):
Investment income		0		0
Interest expense		(139)		(414)
Amortization of debt issuance costs		0		0
Other income (expenses)		0		0
Other income (expenses), net		(139)		(414)
Income before income taxes		(256)		(767)
Income tax (benefit) provision		(60)		(179)
Net income		$ (196)		$ (588)
Earnings per share:
Basic		$ (0.01)		$ (0.01)
Diluted (Note 13)		$ 0		$ (0.02)
Weighted average common shares outstanding:
Basic		0		0
Diluted (Note 13)		0		0
Net income		$ (196)		$ (588)
Other comprehensive income (loss):
Foreign currency translation adjustment		0		0
Comprehensive income		(196)		(588)
Other Adjustments | Product
Revenue:
Revenue		0		0
Other Adjustments | Royalty and other revenue
Revenue:
Revenue		$ 0		$ 0

Restatement of Previously Iss_7

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Consolidated Statements of Stockholders' Equity (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	$ 1,984,438	$ 1,956,859	$ 1,964,845	$ 1,910,700
Net Income (Loss)	(654)	16,923	8,355	52,046
Translation adjustment	9,822	(5,880)	3,185	(8,972)
Balance	2,016,686	1,973,743	2,016,686	1,973,743
Accumulated Other Comprehensive Loss
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	(44,445)	(37,486)	(37,808)	(34,394)
Translation adjustment		(5,880)		(8,972)
Balance	(34,623)	(43,366)	(34,623)	(43,366)
Retained Earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance	441,877	432,395	432,868	397,272
Net Income (Loss)	(654)	16,923	8,355	52,046
Balance	$ 441,223	449,318	441,223	449,318
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance		1,970,926	1,971,203	1,910,700
Net Income (Loss)		18,172		67,065
Translation adjustment		(6,382)		(9,177)
Balance		1,988,557		1,988,557
Previously Reported | Accumulated Other Comprehensive Loss
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance		(37,189)		(34,394)
Translation adjustment		(6,382)		(9,177)
Balance		(43,571)		(43,571)
Previously Reported | Retained Earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance		446,165		397,272
Net Income (Loss)		18,172		67,065
Balance		464,337		464,337
Revenue Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance		(13,675)	(5,574)
Net Income (Loss)		(1,053)		(14,431)
Translation adjustment		502		205
Balance		(14,226)		(14,226)
Revenue Adjustments | Accumulated Other Comprehensive Loss
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance		(297)
Translation adjustment		502		205
Balance		205		205
Revenue Adjustments | Retained Earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance		(13,378)
Net Income (Loss)		(1,053)		(14,431)
Balance		(14,431)		(14,431)
Other Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance		(392)	$ (784)
Net Income (Loss)		(196)		(588)
Translation adjustment		0		0
Balance		(588)		(588)
Other Adjustments | Retained Earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Balance		(392)
Net Income (Loss)		(196)		(588)
Balance		$ (588)		$ (588)

Restatement of Previously Iss_8

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Statement Of Cash flows (Detail) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2024	Sep. 01, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net Income (Loss)	$ (654)		$ 16,923	$ 8,355	$ 52,046
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization				51,306	51,295
Amortization of debt discount and issuance costs				11,628	1,373
Stock-based compensation	23,055	$ 22,400	6,373	41,711	19,110
Deferred income taxes, net				(4,163)	(9,268)
Contingent consideration	0		(34,292)	0	(31,266)
Non-cash interest income				0	(2,023)
Operating lease right of use asset amortization				12,749	10,203
Other				107	1,275
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable				(4,631)	8,315
Inventories				20,131	25,979
Prepaid expenses and other assets				(2,609)	(12,749)
Other assets					(707)
Accounts payable				1,780	(8,619)
Accrued expenses				5,360	(12,514)
Operating lease liabilities				(5,849)	(7,676)
Long-term liabilities				(141)	79
Total cash provided by operating activities				136,218	84,853
Cash flows from investing activities:
Acquisitions, net of cash acquired				0	(27,843)
Proceeds from maturity of marketable securities held to maturity				0	102,323
Additions to capitalized software costs				(2,774)	(2,736)
Purchases of property, plant and equipment				(20,137)	(25,135)
Purchase of intellectual property					0
Other investing activities					21
Total cash (used in) provided by investing activities				(21,621)	46,630
Cash flows from financing activities:
Proceeds from exercise of stock options				2,366	356
Payment of tax withholding obligation on vesting of restricted stock				(9,403)	(12,178)
Repayment of Convertible Senior Notes				(69,939)	(33)
Payment of earnout consideration				(7,375)	(7,298)
Proceeds from issuance of common stock, net					(13)
Total cash used in financing activities				(84,351)	(19,166)
Effect of exchange rate changes on cash and cash equivalents				2,395	(4,996)
Net increase (decrease) in cash and cash equivalents				32,641	107,321
Cash, cash equivalents and restricted cash, beginning of period				751,323	523,458
Cash and cash equivalents, end of period	$ 783,964		630,779	783,964	630,779
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases				24,087	1,129
Fair value of shares of common stock issued for contingent consideration earnouts				5,742	7,229
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition				$ 0	5,465
Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of shares of common stock issued for contingent consideration earnouts					7,229
Previously Reported
Cash flows from operating activities:
Net Income (Loss)			18,172		67,065
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					50,942
Amortization of debt discount and issuance costs					1,373
Stock-based compensation					19,110
Deferred income taxes, net					(9,756)
Contingent consideration			(34,292)		(31,266)
Non-cash interest income					(2,023)
Operating lease right of use asset amortization					10,203
Other					861
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable					8,315
Inventories					25,979
Prepaid expenses and other assets					(10,733)
Other assets					(707)
Accounts payable					(8,619)
Accrued expenses					(28,294)
Operating lease liabilities					(7,676)
Long-term liabilities					79
Total cash provided by operating activities					84,853
Cash flows from investing activities:
Acquisitions, net of cash acquired					(27,843)
Proceeds from maturity of marketable securities held to maturity					102,323
Additions to capitalized software costs					(2,736)
Purchases of property, plant and equipment					(25,135)
Purchase of intellectual property					0
Other investing activities					21
Total cash (used in) provided by investing activities					46,630
Cash flows from financing activities:
Proceeds from exercise of stock options					356
Payment of tax withholding obligation on vesting of restricted stock					(12,178)
Repayment of Convertible Senior Notes					(33)
Payment of earnout consideration					(7,298)
Proceeds from issuance of common stock, net					(13)
Total cash used in financing activities					(19,166)
Effect of exchange rate changes on cash and cash equivalents					(4,996)
Net increase (decrease) in cash and cash equivalents					107,321
Cash, cash equivalents and restricted cash, beginning of period					523,458
Cash and cash equivalents, end of period			630,779		630,779
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases					1,129
Previously Reported | FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition					5,465
Previously Reported | Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of shares of common stock issued for contingent consideration earnouts					7,229
Revenue Adjustments
Cash flows from operating activities:
Net Income (Loss)			(1,053)		(14,431)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					0
Amortization of debt discount and issuance costs					0
Stock-based compensation					0
Deferred income taxes, net					667
Contingent consideration			0		0
Non-cash interest income					0
Operating lease right of use asset amortization					0
Other					0
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable					0
Inventories					0
Prepaid expenses and other assets					(2,016)
Other assets					0
Accounts payable					0
Accrued expenses					15,780
Operating lease liabilities					0
Long-term liabilities					0
Total cash provided by operating activities					0
Cash flows from investing activities:
Acquisitions, net of cash acquired					0
Proceeds from maturity of marketable securities held to maturity					0
Additions to capitalized software costs					0
Purchases of property, plant and equipment					0
Purchase of intellectual property					0
Other investing activities					0
Total cash (used in) provided by investing activities					0
Cash flows from financing activities:
Proceeds from exercise of stock options					0
Payment of tax withholding obligation on vesting of restricted stock					0
Repayment of Convertible Senior Notes					0
Payment of earnout consideration					0
Proceeds from issuance of common stock, net					0
Total cash used in financing activities					0
Effect of exchange rate changes on cash and cash equivalents					0
Net increase (decrease) in cash and cash equivalents					0
Cash, cash equivalents and restricted cash, beginning of period					0
Cash and cash equivalents, end of period			0		0
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases					0
Revenue Adjustments | FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition					0
Revenue Adjustments | Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of shares of common stock issued for contingent consideration earnouts					0
Other Adjustments
Cash flows from operating activities:
Net Income (Loss)			(196)		(588)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					353
Amortization of debt discount and issuance costs					0
Stock-based compensation					0
Deferred income taxes, net					(179)
Contingent consideration			0		0
Non-cash interest income					0
Operating lease right of use asset amortization					0
Other					414
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable					0
Inventories					0
Prepaid expenses and other assets					0
Other assets					0
Accounts payable					0
Accrued expenses					0
Operating lease liabilities					0
Long-term liabilities					0
Total cash provided by operating activities					0
Cash flows from investing activities:
Acquisitions, net of cash acquired					0
Proceeds from maturity of marketable securities held to maturity					0
Additions to capitalized software costs					0
Purchases of property, plant and equipment					0
Purchase of intellectual property					0
Other investing activities					0
Total cash (used in) provided by investing activities					0
Cash flows from financing activities:
Proceeds from exercise of stock options					0
Payment of tax withholding obligation on vesting of restricted stock					0
Repayment of Convertible Senior Notes					0
Payment of earnout consideration					0
Proceeds from issuance of common stock, net					0
Total cash used in financing activities					0
Effect of exchange rate changes on cash and cash equivalents					0
Net increase (decrease) in cash and cash equivalents					0
Cash, cash equivalents and restricted cash, beginning of period					0
Cash and cash equivalents, end of period			$ 0		0
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases					0
Other Adjustments | FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition					0
Other Adjustments | Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of shares of common stock issued for contingent consideration earnouts					$ 0

Restatement of Previously Iss_9

Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Statement Of Cash flows (Parenthetical) (Detail) - shares		9 Months Ended
	Apr. 17, 2023	Sep. 30, 2023
FlexBiosys, Inc.
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Shares of common stock issued for acquisition	31,415	31,415
Avitide, Inc.
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Shares of common stock issued for acquisition		42,621

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial assets and financial liabilities measured at fair value on a recurring basis (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current contingent consideration	$ 13,936	$ 12,983
Noncurrent contingent consideration		14,070
Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	669,347	658,574
Level 1 | Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	669,347	658,574
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current contingent consideration	$ 13,936	12,983
Noncurrent contingent consideration		$ 14,070

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Thousands			9 Months Ended
	Dec. 14, 2023	Apr. 17, 2023	Sep. 30, 2024	Dec. 31, 2023	Jul. 31, 2019
0.375% Convertible Senior Notes due 2024
Summary Of Significant Accounting Policies [Line Items]
Principal amount					$ 287,500
Notes, carrying value				$ 69,500
Fair value of convertible senior notes				109,800
1.00% Convertible Senior Notes due 2028
Summary Of Significant Accounting Policies [Line Items]
Principal amount	$ 290,100
Notes, carrying value			$ 521,600	510,100
Fair value of convertible senior notes			553,300	596,000
Notes for cash	290,100
1.00% Convertible Senior Notes due 2028 | Private Placement
Summary Of Significant Accounting Policies [Line Items]
Principal amount	600,000
1.00% Convertible Senior Notes due 2028 | Exchange Transaction
Summary Of Significant Accounting Policies [Line Items]
Debt istrument cancelled	309,900
1.00% Convertible Senior Notes due 2028 | Subscription Transaction
Summary Of Significant Accounting Policies [Line Items]
Principal amount	290,100
2019 Notes [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt Intrument Exchange Amount	$ 217,700
Money Market
Summary Of Significant Accounting Policies [Line Items]
Assets, fair value			669,347	$ 658,574
Avitide, Inc.
Summary Of Significant Accounting Policies [Line Items]
Business combination contingent consideration			125,000
FlexBiosys, Inc.
Summary Of Significant Accounting Policies [Line Items]
Business combination contingent consideration		$ 6,600	42,000
Metenova Holding AB
Summary Of Significant Accounting Policies [Line Items]
Business combination contingent consideration			$ 10,000

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Reconciliation of the Change in the Fair Value of Contingent Consideration - Earnout (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payment of contingent consideration earnout	$ 0	$ (34,292)	$ 0	$ (31,266)
Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at December 31, 2023			27,053
Payment of contingent consideration earnout			(13,117)
Decrease in fair value of contingent consideration earnouts			0
Balance at September 30, 2024	$ 13,936		$ 13,936

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Contingent Consideration Earnout Expect to be Required to Settle Include Significant Unobservable Inputs (Detail) - Contingent Consideration - USD ($) $ in Thousands		Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 13,936	$ 27,053
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 361
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	5.80%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	13.90%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Revenue & Volume Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	5.10%
Manufacturing line expansions | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Probability of success		100%
Manufacturing line expansions | Monte Carlo Simulation | Fair Value, Recurring | Probability of Success
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	100%
Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 3,897
Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	6.30%
Minimum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		5.80%
Volatility		12.50%
Revenue and volume discount rate		2.50%
Minimum | Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.10%
Maximum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		7.20%
Volatility		24.60%
Revenue and volume discount rate		9.30%
Maximum | Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.40%
Avitide, Flexbiosys and Metenova | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 9,678
Probability of success		100%
Avitide, Flexbiosys and Metenova | Monte Carlo Simulation | Fair Value, Recurring | Probability of Success
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	100%
Avitide, Flexbiosys and Metenova | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	5.90%
Avitide, Flexbiosys and Metenova | Minimum | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		5.80%
Avitide, Flexbiosys and Metenova | Maximum | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		5.90%
[1] Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands			3 Months Ended	9 Months Ended
	Oct. 02, 2023	Apr. 17, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill			$ 987,620	$ 987,620		$ 987,120
Metenova Holding AB
Business Acquisition [Line Items]
Cash consideration	$ 164,500
Shares of common stock issued for acquisition	52,299
Value of common stock issued	$ 172,600
Business combination contingent consideration				10,000
Net liabilities assumed	1,900
Business combination, intangible assets	58,800
Intangible Asset Residual Value	115,700
Transaction costs			6,500	6,500
Business combination, acquisition related costs			400	3,000
Goodwill			115,722	115,722
Metenova Holding AB | Common Stock
Business Acquisition [Line Items]
Value of common stock issued	$ 8,100
FlexBiosys
Business Acquisition [Line Items]
Business combination date of acquistion		Apr. 17, 2023
Cash consideration		$ 29,000
Business Combination, Indemnification Assets, Range of Outcomes, Value, High		$ 6,300
Shares of common stock issued for acquisition		31,415			31,415
Value of common stock issued		$ 41,000
Business combination contingent consideration		6,600		42,000
Net liabilities assumed		14,100
Business combination, intangible assets		12,600
Intangible Asset Residual Value		14,300
Transaction costs			1,100	1,100
Business combination, acquisition related costs			0	0
Goodwill			$ 14,321	$ 14,321
FlexBiosys | Common Stock
Business Acquisition [Line Items]
Value of common stock issued		$ 5,400

Acquisitions - Fair Value of Ne

Acquisitions - Fair Value of Net Assets Acquired (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Oct. 02, 2023	Apr. 17, 2023
Business Acquisition [Line Items]
Goodwill	$ 987,620	$ 987,120
Metenova Holding AB
Business Acquisition [Line Items]
Cash and cash equivalents	5,768
Accounts receivable	3,730
Inventory	4,477
Prepaid expenses and other current assets	470
Property and equipment	433
Operating lease right of use asset	615
Business combination, intangible assets			$ 58,800
Goodwill	115,722
Accounts payable	(1,432)
Accrued liabilities	(2,934)
Operating lease liability	(275)
Noncurrent deferred tax liability	(12,481)
Noncurrent operating lease liability	(255)
Fair value of net assets acquired	172,600
Metenova Holding AB | Customer relationships
Business Acquisition [Line Items]
Business combination, intangible assets	12,659
Metenova Holding AB | Developed technology
Business Acquisition [Line Items]
Business combination, intangible assets	44,377
Metenova Holding AB | Trademark and tradename
Business Acquisition [Line Items]
Business combination, intangible assets	939
Metenova Holding AB | Non-competition agreements
Business Acquisition [Line Items]
Business combination, intangible assets	787
FlexBiosys
Business Acquisition [Line Items]
Cash and cash equivalents	1,090
Accounts receivable	683
Inventory	667
Prepaid expenses and other current assets	35
Property and equipment	12,034
Operating lease right of use asset	3,537
Business combination, intangible assets				$ 12,600
Goodwill	14,321
Other noncurrent assets	10
Accounts payable	(136)
Accrued liabilities	(314)
Operating lease liability	(39)
Noncurrent operating lease liability	(3,498)
Fair value of net assets acquired	41,030
FlexBiosys | Customer relationships
Business Acquisition [Line Items]
Business combination, intangible assets	2,530
FlexBiosys | Developed technology
Business Acquisition [Line Items]
Business combination, intangible assets	9,860
FlexBiosys | Trademark and tradename
Business Acquisition [Line Items]
Business combination, intangible assets	30
FlexBiosys | Non-competition agreements
Business Acquisition [Line Items]
Business combination, intangible assets	$ 220

Acquisitions - Estimated Useful

Acquisitions - Estimated Useful Life and Fair Value (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Metenova Holding AB
Business Acquisition [Line Items]
Fair Value	$ 58,762
Metenova Holding AB | Customer relationships
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	15 years
Fair Value	$ 12,659
Metenova Holding AB | Developed technology
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	15 years
Fair Value	$ 44,377
Metenova Holding AB | Trademark and tradename
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	15 years
Fair Value	$ 939
Metenova Holding AB | Non-competition agreements
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	2 years
Fair Value	$ 787
FlexBiosys
Business Acquisition [Line Items]
Fair Value	$ 12,640
FlexBiosys | Customer relationships
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	12 years
Fair Value	$ 2,530
FlexBiosys | Developed technology
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	16 years
Fair Value	$ 9,860
FlexBiosys | Trademark and tradename
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	4 years
Fair Value	$ 30
FlexBiosys | Non-competition agreements
Business Acquisition [Line Items]
Weighted Average Useful Life (in years)	5 years
Fair Value	$ 220

Restructuring Plan - Additional

Restructuring Plan - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 2,918	$ 24,012	$ 5,311	$ 24,012

Restructuring Plan - Summary of

Restructuring Plan - Summary of Restructuring Activities by Type of Cost (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 2,918	$ 24,012	$ 5,311	$ 24,012
Severance and Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	654	2,830	2,811	2,830
Inventory Write-Off
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		17,185		17,185
Accelerated Depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		3,816	19	3,816
Facility and Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	2,264	181	2,481	181
Cost of goods sold
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,484	22,711	2,556	22,711
Cost of goods sold | Severance and Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	23	1,654	876	1,654
Cost of goods sold | Inventory Write-Off
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		17,185		17,185
Cost of goods sold | Accelerated Depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		3,788	19	3,788
Cost of goods sold | Facility and Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,461	84	1,661	84
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		35	449	35
Research and development | Severance and Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		34	449	34
Research and development | Inventory Write-Off
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		0		0
Research and development | Accelerated Depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		1	0	1
Research and development | Facility and Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		0	0	0
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,668	1,266	2,540	1,266
Selling, general and administrative | Severance and Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	631	1,142	1,486	1,142
Selling, general and administrative | Inventory Write-Off
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		0		0
Selling, general and administrative | Accelerated Depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		27	0	27
Selling, general and administrative | Facility and Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,037	$ 97	1,054	$ 97
Other (income) expenses
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	(234)		(234)
Other (income) expenses | Severance and Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0		0
Other (income) expenses | Accelerated Depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs			0
Other (income) expenses | Facility and Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ (234)		$ (234)

Restructuring Plan - Summary _2

Restructuring Plan - Summary of Activity Related to Restructuring Plan (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring Liability December 31, 2023			$ 464
Restructuring Costs	$ 2,918	$ 24,012	5,311	$ 24,012
Amounts Paid in 2024			(5,745)
Noncash Restructuring Items			166
Restructuring Liability September 30, 2024	196		196
Severance & Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Liability December 31, 2023			464
Restructuring Costs	654	2,830	2,811	2,830
Amounts Paid in 2024			(3,030)
Noncash Restructuring Items			(49)
Restructuring Liability September 30, 2024	196		196
Accelerated Depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Liability December 31, 2023			0
Restructuring Costs		$ 3,816	19	$ 3,816
Amounts Paid in 2024			0
Noncash Restructuring Items			(19)
Restructuring Liability September 30, 2024	0		0
Facility and other exit costs
Restructuring Cost and Reserve [Line Items]
Restructuring Liability December 31, 2023			0
Restructuring Costs			2,481
Amounts Paid in 2024			(2,715)
Noncash Restructuring Items			234
Restructuring Liability September 30, 2024	$ 0		$ 0

Revenue Recognition - Summary o

Revenue Recognition - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 154,871	$ 141,192	$ 466,892	$ 465,741
Product Revenue
Disaggregation of Revenue [Line Items]
Total revenue	154,834	141,156	466,784	465,630
Royalty and Other Income
Disaggregation of Revenue [Line Items]
Total revenue	$ 37	$ 36	$ 108	$ 111

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Balances from contracts with customers only:
Accounts receivable	$ 129,026	$ 124,161
Deferred revenue (included in accrued liabilities and other noncurrent liabilities in the condensed consolidated balance sheets)	16,884	17,536
Revenue recognized during periods presented relating to:
The beginning deferred revenue balance	$ 15,365	$ 18,751

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Changes in Carrying Value of Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Goodwill [Line Items]
Balance	$ 987,120
Cumulative translation adjustment	556
Balance	987,620
Metenova Holding AB [Member]
Goodwill [Line Items]
Measurement period adjustment - Metenova	(56)
Balance	$ 115,722

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Finite-Lived Intangible Liabilities [Line Items]
Impairment of intangible assets			$ 0
Amortization of Intangible Assets	$ 8.6	$ 7.6	$ 26	$ 22.8

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Intangible Assets [Line Items]
Gross Carrying Value	$ 539,445	$ 539,396
Gross Carrying Value	540,145	540,096
Accumulated Amortization	(159,391)	(133,139)
Accumulated Amortization	(159,391)	(133,139)
Net Carrying Value	380,054	406,257
Net Carrying Value	$ 380,754	$ 406,957
Weighted Average Useful Life (in years)	15 years	15 years
Trademark
Intangible Assets [Line Items]
Gross Carrying Value	$ 700	$ 700
Net Carrying Value	700	700
Technology - developed
Intangible Assets [Line Items]
Gross Carrying Value	256,482	256,536
Accumulated Amortization	(56,803)	(44,633)
Net Carrying Value	$ 199,679	$ 211,903
Weighted Average Useful Life (in years)	16 years	16 years
Patents
Intangible Assets [Line Items]
Gross Carrying Value	$ 240	$ 240
Accumulated Amortization	(240)	(240)
Net Carrying Value	$ 0	$ 0
Weighted Average Useful Life (in years)	8 years	8 years
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Value	$ 270,049	$ 269,949
Accumulated Amortization	(97,210)	(83,963)
Net Carrying Value	$ 172,839	$ 185,986
Weighted Average Useful Life (in years)	15 years	15 years
Trademarks
Intangible Assets [Line Items]
Gross Carrying Value	$ 8,757	$ 8,757
Accumulated Amortization	(2,183)	(1,789)
Net Carrying Value	$ 6,574	$ 6,968
Weighted Average Useful Life (in years)	19 years	19 years
Other intangibles
Intangible Assets [Line Items]
Gross Carrying Value	$ 3,917	$ 3,914
Accumulated Amortization	(2,955)	(2,514)
Net Carrying Value	$ 962	$ 1,400
Weighted Average Useful Life (in years)	3 years	3 years

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization Expense for Amortized Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Liabilities [Line Items]
2024 (remaining three months)	$ 8,620
2025	34,354
2026	34,000
2027	33,965
2028	33,863
2029 and thereafter	235,252
Net Carrying Value	$ 380,054	$ 406,257

Consolidated Balance Sheet De_3

Consolidated Balance Sheet Detail - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Assets held for sale			$ 1	$ 1
Gain on sale of property	$ 0.2	$ 0.2

Consolidated Balance Sheet De_4

Consolidated Balance Sheet Detail - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventory [Line Items]
Raw materials	$ 106,843	$ 123,598
Work-in-process	6,794	4,492
Finished products	68,828	74,231
Total inventories, net	$ 182,465	$ 202,321

Consolidated Balance Sheet De_5

Consolidated Balance Sheet Detail - Property, Plant and Equipment, Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Land	$ 893	$ 992
Buildings	725	1,667
Leasehold improvements	142,506	126,663
Equipment	120,029	114,606
Furniture, fixtures and office equipment	10,035	9,077
Computer hardware and software	40,790	35,528
Construction in progress	40,241	47,086
Other	488	544
Total property, plant and equipment	355,707	336,163
Less - Accumulated depreciation	(153,124)	(128,723)
Total property, plant and equipment, net	$ 202,583	$ 207,440

Consolidated Balance Sheet De_6

Consolidated Balance Sheet Detail - Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule of Accrued Liabilities [Line Items]
Employee compensation	$ 28,104	$ 16,660
Deferred revenue	16,446	17,067
Income taxes payable	148	6,814
Other	16,204	16,772
Total accrued liabilities	$ 60,902	$ 57,313

Convertible Senior Notes - Addi

Convertible Senior Notes - Additional Information (Detail)			3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 14, 2023 USD ($)	Jul. 19, 2019 USD ($)	Sep. 30, 2024 USD ($) Days $ / shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 06, 2023 $ / shares	Jul. 31, 2019 USD ($)
Debt Instrument [Line Items]
Amortization of debt issuance costs			$ 429,000	$ 459,000	$ 1,432,000	$ 1,373,000
Proceeds from issuance of common stock, net of issuance costs						$ (13,000)
1.00% Convertible Senior Notes due 2028
Debt Instrument [Line Items]
Notes issued	$ 290,100,000
Notes, interest rate			1%		1%
Notes for cash	290,100,000
Unamortized debt issuance costs			$ 7,132,000		$ 7,132,000		$ 8,400,000
Aggregate debt discount			$ 71,261,000		$ 71,261,000		81,457,000
Notes conversion ratio per $1,000 principal amount					4,924.7000
Notes initial conversion price | $ / shares			$ 203.06		$ 203.06
Premium over sale price					30%
Closing price of common stock | $ / shares								$ 156.2
Interest repayment terms					Interest is payable semi-annually in arrears on each of June 15 and December 15, which commenced on June 15, 2024
Notes, due date					Dec. 15, 2028
Notes, carrying value			$ 521,600,000		$ 521,600,000		510,100,000
Fair value of the note			553,300,000		553,300,000		596,000,000
1.00% Convertible Senior Notes due 2028 | Common Stock
Debt Instrument [Line Items]
Notes issued			1,000		1,000
1.00% Convertible Senior Notes due 2028 | Exchange And Subscription Agreements
Debt Instrument [Line Items]
Notes issued	600,000,000
1.00% Convertible Senior Notes due 2028 | Subscription Transactions
Debt Instrument [Line Items]
Notes issued	290,100,000
Proceeds from issuance of convertible senior notes, net of costs	276,100,000
Notes for cash	290,100,000
Payment of debt issuance costs	13,900,000
Proceeds from issuance of common stock, net of issuance costs	14,400,000
1.00% Convertible Senior Notes due 2028 | Exchanged 2019 Notes
Debt Instrument [Line Items]
Loss on extinguishment of debt	29,600,000						12,700,000
Debt instrument exchanged amount	217,700,000
Modification of debt	188,100,000
Unamortized debt issuance costs							100,000
1.00% Convertible Senior Notes due 2028 | Modified 2019 Notes
Debt Instrument [Line Items]
Notes issued			68,900,000		68,900,000		78,700,000
Unamortized debt issuance costs							7,700,000
Aggregate debt discount			71,300,000		71,300,000		81,500,000
Payment of debt issuance costs	6,200,000
Amortization of debt issuance costs	7,700,000
1.00% Convertible Senior Notes due 2028 | Modified 2019 Notes | Additional Paid-In Capital
Debt Instrument [Line Items]
Conversion of Convertible Securities Stock Issued | value	$ 2,800,000
1.00% Convertible Senior Notes due 2028 | Modified 2019 Notes | Fair Value Of Embedded Conversion Option
Debt Instrument [Line Items]
Conversion of Convertible Securities Stock Issued | value					$ 2,400,000		2,800,000
1.00% Convertible Senior Notes due 2028 | 2023 Notes
Debt Instrument [Line Items]
Notes redemption price					100%
Notes, carrying value			521,600,000		$ 521,600,000		510,100,000
0.375% Convertible Senior Notes due 2024
Debt Instrument [Line Items]
Notes issued		$ 287,500,000	69,500,000		69,500,000		69,700,000		$ 287,500,000
Debt conversion original debt amount					200,000
Proceeds from issuance of convertible senior notes, net of costs		278,500,000
Unamortized debt issuance costs			$ 0		$ 0		248,000
Notes, carrying value							69,500,000
Fair value of the note							109,800,000
Additional Notes issued		$ 37,500,000
Debt Instrument, Convertible, Threshold Trading Days | Days			20
Debt Instrument, Convertible, Threshold Consecutive Trading Days | Days			30
Notes threshold percentage of stock price trigger			130%
Debt conversion, stock issued as premium | shares					100,942
Debt conversion, cash paid for principal amount and interest					$ 69,600,000
0.375% Convertible Senior Notes due 2024 | Exchange Transaction
Debt Instrument [Line Items]
Notes issued							$ 69,700,000

Convertible Senior Notes - Conv

Convertible Senior Notes - Convertible Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 14, 2023
Debt Instrument [Line Items]
Total convertible senior notes	$ 521,607	$ 510,143
1.00% Convertible Senior Notes due 2028
Debt Instrument [Line Items]
Principal amount	600,000	600,000	$ 309,900
Unamortized debt discount	(71,261)	(81,457)
Unamortized debt issuance costs	(7,132)	(8,400)
Total convertible senior notes	521,607	510,143
0.375% Convertible Senior Notes due 2024
Debt Instrument [Line Items]
Principal amount	0	69,700	$ 217,700
Unamortized debt issuance costs	0	(248)
Total convertible senior notes	$ 0	$ 69,452

Convertible Senior Notes - Sche

Convertible Senior Notes - Schedule of convertible note interest expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Amortization of debt discount			$ 11,628	$ 1,373
2023 Notes
Debt Instrument [Line Items]
Contractual interest expense	$ 1,500		4,500
Amortization of debt discount	3,473		10,197
Amortization of debt issuance costs	410		1,190
Total	$ 5,383		$ 15,887
Effective interest rate of the liability component	4.39%		4.39%
2019 Notes
Debt Instrument [Line Items]
Contractual interest expense	$ 11	$ 269	$ 141	808
Amortization of debt issuance costs	19	459	243	1,373
Total	$ 30	$ 728	$ 384	$ 2,181
Effective interest rate of the liability component	1%	1%	1%	1%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2024

Sep. 01, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Jun. 28, 2024

Jun. 12, 2024

Apr. 30, 2024

Mar. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2018

Stockholders Equity Note Disclosure [Line Items]

Aggregate intrinsic value of stock options exercised

$ 4,700

$ 3,400

Weighted average grant date fair value of share-based awards granted

$ 89.09

$ 85.7

Weighted average grant date fair value of restricted stock units granted

$ 180.02

Total unrecognized compensation cost

$ 62,100

$ 62,100

Unrecognized compensation cost, weighted average remaining requisite service period

2 years 9 months 25 days

Number of unvested options and restricted stock units

2,300,804

2,300,804

Forfeited portion of grants

[1]

32,027

Share recalculated value

$ 136

Stock-based compensation expense

$ 23,055

$ 22,400

$ 6,373

$ 41,711

$ 19,110

Common stock, shares issued

56,026,725

56,026,725

55,766,078

55,557,698

FlexBiosys

Stockholders Equity Note Disclosure [Line Items]

Common stock, shares issued

2,770

Earnout consideration earned

20%

Avitide

Stockholders Equity Note Disclosure [Line Items]

Common stock, shares issued

28,638

Earnout consideration earned

50%

2018 Plan

Stockholders Equity Note Disclosure [Line Items]

Common stock shares reserved for Issuance

2,778,000

Incentive options, vesting period

1,487,289

1,487,289

Unvested Options

Stockholders Equity Note Disclosure [Line Items]

Incentive options, vesting period

5 years

Restricted Stock Units and Performance Stock Units

Stockholders Equity Note Disclosure [Line Items]

Aggregate intrinsic value of restricted stock units vested

$ 25,100

$ 32,300

Weighted average grant date fair value of restricted stock units granted

$ 180.02

$ 174.86

Restricted Stock Unit

Stockholders Equity Note Disclosure [Line Items]

Closing price of common stock

$ 148.82

2024 Grants

Stockholders Equity Note Disclosure [Line Items]

Forfeited portion of grants

32,776

Stock-based compensation expense

$ 17,400

$ 22,400

[1] Includes 13,057 options forfeited pursuant to the 2024 Award Amendment discussed above under “Chief Executive Officer Accounting Modifications” .

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
		Sep. 30, 2024	Sep. 01, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation		$ 23,055	$ 22,400	$ 6,373	$ 41,711	$ 19,110
Cost of goods sold
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation		396		393	1,498	1,506
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation		887		700	2,335	2,095
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	[1]	$ 21,772		$ 5,280	$ 37,878	$ 15,509
[1] Selling, general and administrative stock-based compensation for the three and nine months ended September 30, 2024 includes $ 17.4 million and $ 22.4 million of expense related to the Equity Modification discussed above.

Stockholders' Equity - Stock-_2

Stockholders' Equity - Stock-Based Compensation Expense (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
2024 Grants | Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense related to the equity modification	$ 17.4	$ 22.4

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Option Activity (Detail) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Options Outstanding
Options outstanding at December 31, 2023 | shares	649,130
Granted | shares | shares	77,014
Exercised | shares | shares	(43,725)
Forfeited/expired/cancelled | shares	(32,027)	[1]
Options outstanding at September 30, 2024 /Shares | shares	650,392
Options exercisable at September 30, 2024 | shares | shares	398,851
Vested and expected to vest at September 30, 2024 | shares | shares	644,688	[2]
Weighted-Average Exercise Price Per Share
Options outstanding at December 31, 2023 | $ / shares	$ 85.97
Granted | $ / shares	175.6
Exercised | $ / shares	54.11
Forfeited/expired/cancelled | $ / shares	195.78	[1]
Options outstanding at September 30, 2024 | $ / shares	93.31
Options exercisable at September30, 2024 | $ / shares	76.47
Vested and expected to vest at September 30, 2024 | $ / shares	$ 92.66	[2]
Weighted-Average Remaining Contractual Term (in years)
Vested and expected to vest at September 30, 2024	5 years 3 months 21 days	[2]
Aggregate Intrinsic Value
Vested and expected to vest at September 30, 2024 | $	$ 43,311	[2]
[1] Includes 13,057 options forfeited pursuant to the 2024 Award Amendment discussed above under “Chief Executive Officer Accounting Modifications” . Represents the number of vested options as of September 30, 2024 plus the number of unvested options expected to vest as of September 30, 2024 based on the unvested outstanding options at September 30, 2024 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Option Activity (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2024 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited portion of grants	32,027	[1]
2024 Award Amendment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited portion of grants	13,057
Employee Stock Option | Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8%
Employee Stock Option | Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3%
[1] Includes 13,057 options forfeited pursuant to the 2024 Award Amendment discussed above under “Chief Executive Officer Accounting Modifications” .

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Options Outstanding
Unvested at December 31, 2023 | shares	474,320
Awarded | shares	221,584
Vested | shares	(137,072)	[1]
Forfeited/cancelled | shares	(82,452)	[2]
Unvested at September 30, 2024 | shares	476,380
Vested and expected to vest at September 30, 2024 | shares	415,171	[3]
Weighted Average Grant Date Fair Value
Weighted Average, Unvested at December 31,2023 | $ / shares	$ 155.59
Weighted Average, Awarded | $ / shares	180.02
Weighted Average, Vested | $ / shares	144.8	[1]
Weighted Average, Forfeited/Cancelled | $ / shares	190.45	[2]
Weighted Average, Unvested at September 30, 2024 | $ / shares	164.04
Weighted Average, Vested and expected to vest at September 30, 2024 | $ / shares	$ 162.37	[3]
[1] Includes 1,462 stock units that had vested but not settled as of September 30, 2024. Includes 13,146 RSUs and 6,573 PSUs forfeited pursuant to the 2024 Award Amendment discussed above under ”Chief Executive Officer Accounting M odifications” . Represents the number of vested stock units as of September 30, 2024 plus the number of unvested stock units expected to vest as of September 30, 2024 based on the unvested outstanding stock units at September 30, 2024 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2024 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited	82,452	[1]
Stock units vested	644,688	[2]
Restricted Stock Units and Performance Stock Units | Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8%
Restricted Stock Units and Performance Stock Units | Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3%
Restricted Stock Unit | 2024 Award Amendment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited	13,146
Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vested	1,462
Performance Stock Units | 2024 Award Amendment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited	6,573
[1] Includes 13,146 RSUs and 6,573 PSUs forfeited pursuant to the 2024 Award Amendment discussed above under ”Chief Executive Officer Accounting M odifications” . Represents the number of vested options as of September 30, 2024 plus the number of unvested options expected to vest as of September 30, 2024 based on the unvested outstanding options at September 30, 2024 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
NGL Impact A [Member] | Research and Development Arrangement [Member]
Commitments and Contingencies [Line Items]
Royalty payments	$ 1.1	$ 0.8	$ 2.9	$ 3.1

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2021
Income Taxes [Line Items]
Income tax (benefit) provision	$ (495)	$ (5,542)	$ 3,218	$ 2,796
Effective tax rate	43%	(48.70%)	27.80%	5.10%
Inflation Reduction Act Of Two Thousand Twenty Two [Member]
Income Taxes [Line Items]
Percentage of alternative minimum tax					15%

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 14, 2023	Jul. 31, 2019	Jul. 19, 2019
Common stock excluded from calculation of diluted earnings per share	491,206	301,404	404,989	328,179
Dilutive effect on shares of conversion premium	0	735,150	0	776,339
1.00% Convertible Senior Notes due 2028
Principal amount						$ 290,100
Principal amount	$ 600,000		$ 600,000		$ 600,000	309,900
Cash						290,100
0.375% Convertible Senior Notes due 2024
Principal amount	69,500		69,500		69,700		$ 287,500	$ 287,500
Principal amount	0		0		$ 69,700	$ 217,700
Subsequent to conversion	$ 200		$ 200
Dilutive Options and Stock Units
Common stock excluded from calculation of diluted earnings per share	358,372

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic and Diluted Shares Amounts (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Numerator
Net (loss) income		$ (654)	$ 16,923	$ 8,355	$ 52,046
Denominator
Weighted average shares used in computing net (loss) income per share - basic		56,012	55,766	55,896	55,688
Effect of dilutive shares
Options and stock units		0	439	419	469
Convertible senior notes	[1]	0	735	0	776
Dilutive potential common shares		0	1,174	419	1,245
Denominator for diluted (loss) earnings per share - adjusted weighted average shares used in computing earnings per share - diluted		56,012	56,940	56,315	56,933
(Loss) earnings per share:
Basic		$ (0.01)	$ 0.3	$ 0.15	$ 0.93
Diluted		$ (0.01)	$ 0.3	$ 0.15	$ 0.91
[1] Represents the dilutive impact for the Company's 2019 Notes. As of September 30, 2024, the if-converted value is less than the outstanding principal of the 2023 Notes and are therefore anti-dilutive. Refer to Note 9, "Convertible Senior Notes," above for more information.

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Principal Owner - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Related Party Transaction [Line Items]
Rental expense	$ 0.1	$ 0.1	$ 0.5	$ 0.5
Minimum | Spectrum Inc.
Related Party Transaction [Line Items]
Non controlling ownership interest minimum	5%		5%

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Segment	Sep. 30, 2023 USD ($)	Dec. 31, 2023
Number of operating segments | Segment			1
Accounts receivable, percentage by customer	100%	100%	100%	100%
Revenue	$ 154,871	$ 141,192	$ 466,892	$ 465,741
Sales Revenue
Revenue	$ 0	$ 0	$ 0	$ 0
Customer Concentration Risk | Accounts Receivable [Member] | Customer Number One [Member]
Accounts receivable, percentage by customer			10%		10%
Customer Concentration Risk | Minimum [Member] | Sales Revenue
Accounts receivable, percentage by customer	10%	10%	10%	10%

Segment Reporting - Percentage

Segment Reporting - Percentage of Revenue by Geographic Area (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Concentration Risk [Line Items]
Revenues, percentage by country	100%	100%	100%	100%
Geographic Concentration Risk | Total Revenue | North America
Concentration Risk [Line Items]
Revenues, percentage by country	51%	49%	50%	46%
Geographic Concentration Risk | Total Revenue | Europe
Concentration Risk [Line Items]
Revenues, percentage by country	33%	34%	35%	34%
Geographic Concentration Risk | Total Revenue | APAC/Other
Concentration Risk [Line Items]
Revenues, percentage by country	16%	17%	15%	20%